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ABSTRACT 
Heme is the major iron source for the deadly human pathogen, Group A Streptococcus (GAS). 
During infection, GAS lyses host cells releasing hemoglobin and other hemoproteins. This 
dissertation aims to elucidate the general mechanism by which GAS obtains and utilizes heme as 
an iron source from the host hemoproteins. GAS encodes a heme relay system consisting of Shr, 
Shp and the SiaABC transporter. We specifically determine the role of Shr in the heme uptake 
process, by conducting a detailed functional characterization of its constituent domains. We also 
undertake to solve the long-standing mystery surrounding the catabolism of heme in 
streptococci. The studies presented herein established Shr as a prototype of a new family of 
NEAT-containing hemoproteins receptors. They demonstrate its importance in heme acquisition 
 by GAS and provide a molecular model for heme scavenging and transfer by the protein. We 
show that Shr modulates heme uptake depending on heme availability by a mechanism where 
NEAT1 facilitates fast heme scavenging and delivery to Shp, whereas NEAT2 serves as a 
temporary storage for heme on the bacterial surface. Finally, we identified and characterized for 
the first time, a heme oxygenase (HO) in the Streptococcus genus which was named HupZ. 
Sequence comparison between HupZ and several HOs from different structural families indicates 
that this enzyme is unrelated to any of the previously characterized HOs. However, orthologs of 
the protein are found in other important pathogens. The structure and the catalytic mechanism of 
HupZ suggest that it is the representative of a new family of flavoenzymes capable of degrading 
heme using their reduced flavin cofactor as a source of electrons. Overall, this work contributes 
significant knowledge to the topic of heme utilization by pathogens and importantly, provides 
new direct evidence that associates flavins with heme metabolism in bacteria. Thus it sets a new 
direction in the field and lays the ground for future fundamental and applied discoveries.       
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GENERAL INTRODUCTION 
 
Group A Streptococcus (GAS)  
Also known as Streptococcus pyogenes, GAS is a Gram-positive coccus that grows in 
chains of variable lengths. When grown on blood agar, the bacterium produces hemolysins, 
which achieve complete lysis of red blood cells. This is known as β-hemolysis and results in 
clearing zones around the bacterial colonies. GAS is an important human pathogen that causes a 
large number of diseases with different clinical manifestations. Repeated GAS infections can 
also lead to severe immune sequelae such as acute glomerulonephritis and rheumatic fever [1-3]. 
Cases of non-invasive infections caused by the bacterium worldwide are estimated at 700 million 
each year. Of these, about 650,000 progress to serious invasive infections resulting in about 25% 
mortality [1]. Invasive GAS infections often require substantial treatments including surgical 
procedures. To date no approved commercial vaccine is available against streptococcal infections 
[4,5]. The emm gene encodes the antigenically variable surface M-protein, which serves as a 
basis for GAS classification into serotypes. More than 100 M-types have been identified [2,6].  
The most common disease caused by GAS is pharyngitis or “strep-throat”. It is often 
associated with symptoms such as sore throat, enlarged and tender lymph nodes in the neck, 
headache, fever, malaise and sometimes abdominal pain. Several rapid tests based on bacterial 
surface determinants or throat cultures are used to diagnose GAS infections [2]. Penicillin is the 
preferred drug for the treatment of GAS pharyngitis, but alternative antibiotics such as 
amoxicillin, erythromycin or oral cephalosporins are used in case of allergy to penicillin. Other 
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non-invasive GAS illnesses include the skin infections impetigo and cellulitis, and the acute 
inflammation of the skin and superficial lymphatic vessels erysipelas [7]. Non-invasive GAS 
diseases can progress to life-threatening invasive infections, which may also occur as a result of 
a direct inoculation due to penetrating injuries. One of the most severe invasive GAS infections 
is the streptococcal gangrene or necrotizing fasciitis, also known as “flesh-eating disease”. The 
common clinical manifestations of the disease are severe pain at the site of infection even 
without an obvious sign of skin break, swelling, fever, confusion, stretched and discolored 
overlying skin. Successful treatment of necrotizing fasciitis dependents on the early diagnosis of 
the illness and requires timely and intense surgical procedures in conjunction with antimicrobial 
treatments [7,8].  
GAS owes its ability to cause a wide variety of diseases to a multitude of virulence 
factors. Few examples include the M-protein, which mediates the attachment of the bacteria to 
host’s epithelial cells and participates in the bacteria resistance to opsonophagocytosis. Escaping 
phagocytosis is accomplished through binding of molecules such as fibrinogen, C4b-binding 
protein, immunoglobulin Fc portion and the H factor, which inhibits the complement system [9-
11]. A capsule composed of hyaluronic acid, a normal component of human tissue, surrounds 
invasive GAS strains allowing them to escape the host immune response [12,13]. The 
streptococcal pyrogenic exotoxins (SPEs) are superantigens that can trigger massive uncontrolled 
release of cytokines and lead to septic shock. Several enzymes produced by GAS also facilitate 
the breaking down of DNA, blood clots and proteins including immunoglobulins. GAS exotoxins 
streptolysins O and S produce pores in the membrane of leukocytes and erythrocytes, causing 
their lysis and the release of hemoglobin which can serve as a nutrient to the pathogen [14-17].   
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Heme uptake by bacteria  
Iron is an essential micronutrient for nearly all living systems including bacteria. In many 
enzymes, iron is a catalytic center involved in redox reactions, which carry out vital cellular 
processes. These include electron transport, DNA and amino acids synthesis, photosynthesis, 
activation of oxygen and peroxide reduction. Iron is one of the most abundant elements on earth 
and exists mainly in the oxidized ferric (Fe3+) or the reduced ferrous (Fe2+) forms. Fe3+ is highly 
insoluble and represents the most predominant iron species in aerobic and neutral pH conditions. 
In contrast, Fe2+ is more soluble but is present only in a limited number of anoxic and strongly 
acidic habitats. Therefore, in spite of its abundance, iron is biologically unavailable in the 
environments inhabited by the vast majority of microorganisms [18-20].  
In mammalian hosts, bacteria are also confronted with iron-restricted environments, 
where free iron is sequestered in extracellular (transferrin, lactoferrin) and intracellular (ferritin) 
host proteins with high affinity for the metal. However, the most abundant source of iron in 
mammals consists of heme, an iron-protoporphyrin IX molecule. It is a hydrophobic tetrapyrrole 
with an iron center that can partition into membranes, thus impairing lipid bilayers. Free heme 
also induces non-enzymatic redox reactions which generate toxic amounts of reactive radicals 
causing severe cell damage [21]. Because of its toxicity, only minute amount of free heme is 
allowed intracellularly or in the blood. The large majority of heme is sequestered by host 
proteins, mainly hemoglobin (Hb), a tetrameric protein with two α- and two β-chains. Each 
subunit of the tetramer binds one heme molecule. Hb is confined in erythrocytes where it serves 
as the oxygen transporter in its reduced form, oxyhemoglobin. When released from the red blood 
cells,  the tetrameric Hb spontaneously oxidizes to the dimeric methemoglobin (metHb) [22]. 
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The total blood Hb concentration in healthy human adult is estimated between 1.9 and 2.3 mM, 
suggesting a relative abundance [23]. Though, it remains highly unavailable to pathogens, as free 
extracellular Hb is readily scavenged by the serum protein, haptoglobin [24].   
To survive the hostile iron-restricted conditions they face during infection, pathogens 
evolved sophisticated machineries to scavenge and import heme from host hemoproteins that are 
released upon hemolysis and tissue damage. Strategies used by many Gram-negative pathogens 
involve hemophores, which are extracellular bacterial proteins secreted in the environment to 
bind free heme or to scavenge heme from host proteins. The heme-bound hemophore 
subsequently recognizes and delivers its heme to a specific receptor at the cell surface, leading to 
heme import inside the cell [20,25]. Examples of hemophore-mediated heme uptake mechanisms 
are described in Gram-negative pathogens Serratia marcescens, Pseudomonas aeruginosa, 
Yersinia enterocolitica and Hemophilus influenza [26-31]. Some Gram-negative organisms also 
rely on outer-membrane receptors for heme acquisition. Examples include HmbR and HpuA in 
Neisseria species, ChuA in E. coli and HutA in Vibrio cholerae [32-36].  
The predominant heme uptake mechanism adopted by Gram-positive organisms uses a 
protein relay. Heme is obtained from host molecules by a surface receptor, then transferred in a 
cascade manner through the thick peptidoglycan layers to a cognate ABC transporter, which 
carries it across the cytoplasmic membrane [37,38]. Heme capture and transfer by surface 
receptors are in the vast majority of cases mediated by a protein domain referred to as NEAT 
(NEAr-iron Transporter). This protein module is encoded in a variable copy number in the 
genome of several Gram-positives, in close vicinity of iron ABC transporters. NEAT domains 
are approximately 125 amino acids long, sharing low primary sequence homology and a 
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predicted secondary structure of mostly β-strands [39]. Heme acquisition systems that employ 
NEAT-containing receptors are widely studied in Staphylococcus aureus, Bacillus species and 
Listeria monocytogenes [37-39]. In addition to these surface receptors, secreted NEAT-
hemophores are also found in Gram-positives. Some examples are illustrated by IsdX1 and 
IsdX2 in Bacillus anthracis [40,41]. Recently, heme relays which do not involve NEAT-
containing receptors were reported in Corynebacterium diphteriae and Mycobacterium 
tuberculosis [42,43]. 
 
The Sia system 
GAS utilizes heme and host hemoproteins as iron source during infection [44]. The two 
known heme acquisition pathways in GAS involve of the streptococcal iron uptake (siu) and the 
streptococcal iron acquisition (sia) systems [45,46]. The sia system consists of a conserved ten-
gene operon which is directly repressed by the iron-dependent regulator MtsR [45,47] (fig. 1A). 
The first gene in the operon encodes Shr (streptococcal hemoproteins receptor), a 145 kDa 
composite surface protein. Shr contains two NEAT domains, a series of leucin-rich repeats 
located between the NEAT domains and a unique N-terminus region (NTD) with two copies of a 
domain of unknown function (DUF1533). Shr C-terminus has a hydrophobic region with a 
positively charged tail that allows the attachment of the protein to the cytoplasmic membrane. 
Unlike other NEAT-containing receptors, Shr does not contain a cell wall-anchoring motif, but is 
exposed to the extracellular environment by protruding through the cell wall. The protein binds a 
wide range of ligands such as heme, Hb, Hb-haptoglobin complex and the extracellular matrix 
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(ECM) proteins fibronectin and laminin [45,48]. Shr does not share significant homology to any 
characterized heme or hemoprotein receptor and its composition and overall domain architecture 
are unique (fig. 1A). The second gene in the sia locus codes for the heme-binding surface protein 
Shp (streptococcal hemoprotein), which has a NEAT-like domain considered as remotely related 
to the NEAT family [49,50]. The third, fourth and fifth genes of the sia operon express a heme 
ABC transporter (SiaABC or HtsABC) where SiaA serves as the heme ligand-binding 
lipoprotein component. Heme coordination in SiaA is mediated by a set of two different axial 
ligands which were recently identified as Met79 and His229 [51,52]. These two residues also 
participate in the release of heme from SiaA in a two-step process that involves a conformational 
change of the protein [52]. From Shr, heme is efficiently transferred to Shp, which in turn gives 
it to SiaABC where it is carried across the cytoplasmic membrane [53,54] (fig. 1B). The function 
of the proteins encoded by the remaining genes of the operon is unknown. The importance of 
heme uptake in GAS virulence was demonstrated in zebrafish and mouse models [46,48,55]. 
While Shr is proposed to participate in heme acquisition, its direct role in the scavenging and 
transfer of heme from hemoproteins to Shp has not been established. In addition, the function 
and importance of the receptor domains are yet to be studied.   
 
Heme oxygenases 
Heme imported into the bacterial cytoplasm is incorporated to intracellular proteins as a 
cofactor, or utilized by the organism as an iron source. In the latter case, the release of iron from 
the porphyrin ring requires the activity of enzymes such as deferrochelatases [56] or heme 
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oxygenases (HO) [57]. However, the mode of action of deferrochelatases in iron release from 
heme is controversial, as contradictory data are provided by different studies [58]. HOs catalyze 
the oxidative cleavage of the methene (meso) carbon bridges of the porphyrin at the positions α, 
β, γ or δ [59]. There are three known mammalian HOs: the inducible HO-1 [60], the constitutive 
HO-2 [60] and HO-3 whose functional relevance is unknown [61].  HO-1 is highly induced by 
chemical agents and a variety of stress conditions and is found in highest concentration in the 
spleen and liver. HO-2 is unresponsive to exogenous stimuli and is preponderant in the brain and 
testes [60]. The two isoforms participate in many physiological processes such as 
neuroprotective activities, iron homeostasis, protection from heme toxicity and oxidative stress 
[60,62-65].  
Heme degradation by HOs requires a source of reducing equivalents, which is provided 
in mammals by NADPH and cytochrome P450 reductase (CPR).  The reaction typically results 
in equimolar quantities of iron, carbon monoxide (CO) and biliverdin (fig. 2). The heme 
catabolite, biliverdin is further converted to bilirubin by biliverdin reductase [60,66]. Each of the 
heme degradation products participates in a number of physiological processes. Iron for example, 
is necessary for erythropoiesis and participates in oxygen transport. Biliverdin and bilirubin are 
powerful antioxidants and CO is a vasodilator that is believed to regulate adequate blood flow 
[63,67-70]. CO is also a signaling molecule that modulates many physiological processes. It was 
shown to be important for the neovascularization during wound healing and it stimulates the 
proliferation of endothelial cells. Moreover, CO has been recognized as a neurotransmitter, an 
immunomodulator and an anti-inflammatory agent [71].   
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Homologues of the human HO-1 are found in bacteria. The first example of bacterial HO, 
named HmuO, was identified and characterized in the pathogen Corynebacterium diphteriae 
[72,73]. Ever since, several other bacterial HOs that share sequence homology with HmuO were 
identified. These include HemO in Neisseria meningitides and Clostridium species, PigA (also 
known as pa-HO) and BphO in Pseudomonas aeruginosa [74-78]. Structurally, this group of 
enzymes consists of monomeric α-helices with similar folds. They specifically degrade heme at 
the α-meso carbon, producing α-biliverdin [66]. The only exception in this group is PigA which 
has an unusual β-meso and δ-meso regiospecificity, producing a mixture of β- and δ-biliverdins 
[77]. The fate of the biliverdin produced in bacterial cell is unknown in most cases, since a 
homologue of mammalian biliverdin reductase has been identified only in cyanobacteria [79,80]. 
Two bacterial HOs, IsdG and IsdI, distinct in structure from the mammalian HO-1 were 
found in Staphylococcus aureus. These enzymes are part of the isd locus which also encodes the 
NEAT-containing hemoprotein receptors and their cognate ABC transporter. IsdG and IsdI are β-
barrel homodimers containing two active sites and catalyze the formation of the atypical product, 
staphylobilin. This contrasts with the canonical production of biliverdin [81-83]. Homologues of 
IsdG with similar structural and biochemical features were characterized in Bradirhyzobium 
japonicum, Mycobacterium tuberculosis, Bacillus anthracis and Staphylococcus lugdunensis 
[84-87]. Additional heme degrading enzymes which do not resemble HO-1 or IsdG-like groups 
of proteins were also described. ChuS in Escherischia coli has a unique structure consisting of 
two central sets of antiparallel β-sheets, each flanked by two pairs of α-helices [88]. Heme 
degradation by ChuS in presence of reducing partners produced CO and spectral features that 
suggest biliverdin production. However, the final products of the reaction were not identified 
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[88]. HemS, a protein with high sequence homology to ChuS was uncovered in Yersinia 
enterocolitica and Bartonella henselae [89,90]. Like ChuS, the products of HemS-catalyzed 
reaction are undefined [90].   
A new family of bacterial HOs with no sequence or structural homologies to previously 
described groups of HOs has been emerging recently. Members of this class of enzymes include 
Cj1613c in Campylobacter jejuni, HugZ in Helicobacter pylori and HutZ in Vibrio cholerae [91-
93]. These enzymes share weak sequence similarities with FMN-binding proteins and exist as 
dimers [92-95]. The crystal structures of HugZ and HutZ are almost identical besides a mismatch 
of one amino acid residue in β6 of HutZ. Both proteins adopt a split β-barrel fold which 
characterizes FMN-binding proteins, but actual FMN binding by these proteins was not 
demonstrated [94,95]. Similar to PigA, HugZ cleaves the heme tetrapyrrole at the δ-meso carbon, 
producing δ-biliverdin and HutZ is hypothesized to produce both β- and δ-biliverdin [92,93]. 
In GAS and all other streptococci, the mechanism by which iron is released from heme is 
unknown. Homologues belonging to the families of the HOs described above have not been 
identified in the Streptococus genus. 
 
Research objectives and significance 
The purpose of this dissertation is to elucidate the general mechanism by which GAS 
obtains and utilizes heme as an iron source from the host hemoproteins. We specifically 
determine the role of Shr in the heme uptake process by conducting a detailed functional 
characterization of the constituent domains of the protein. We also undertake to conduct a 
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comprehensive kinetic study to establish the intra- and inter-molecular flow of heme in the 
streptococcal system. Moreover, we aimed to solve the long-standing mystery surrounding the 
catabolism of heme in streptococci. 
The studies presented herein establish Shr as a prototype of a new family of NEAT-
containing hemoproteins receptor. They demonstrate the importance of Shr in heme acquisition 
by GAS and provide a molecular model for heme scavenging and transfer by the protein. This 
work also brings to light a unique mechanism for the modulation of the heme acquisition 
process. We have identified and begun characterizing the first heme oxygenase in GAS. This 
new enzyme seems to represent a novel HO expressed by several streptococcal pathogens.  
Overall, this dissertation adds a significant knowledge to the blooming topic of heme utilization 
as an iron source by pathogens and lays the ground for future fundamental and applied 
discoveries. 
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CHAPTER I 
 
SHR OF GROUP A STREPTOCOCCUS IS A NEW TYPE OF COMPOSITE NEAT 
PROTEIN INVOLVED IN SEQUESTERING HAEM FROM METHEMOGLOBIN 
 
Introduction 1 
 
Acquisition of iron from host sources is of vital importance to many pathogenic bacteria 
during the course of infection.  Mammalian hosts limit the availability of free extracellular iron 
to levels around 10-18 M [96] by producing iron-chelating proteins such as lactoferrin and 
transferrin or by storing it in ferritin within the cells.  However, nearly 75% of the iron in the 
human body is found in the form of heme, where it is incorporated into the protoporphyrin ring 
and serves as a prosthetic group of hemoglobin, myoglobin, and some enzymes [97,98].  The 
process of obtaining heme from the host by Gram-positive pathogens often involves binding of 
heme or hemoproteins by bacterial receptor proteins which then deliver the heme to a membrane-
bound ABC transporter for translocation to the cytoplasm [20,98].  The first Gram-positive heme 
transporter to be described was the hmu (hemin/hemoglobin utilization) system of 
Corynebacterium diptheriae [99].  The hmuTUV genes share homology with Gram-negative 
heme-ABC transporters such as found in Yersinia pestis [100,101].  HmuT, which is localized to 
the cell membrane, binds hemin or hemoglobin directly; HmuU and V are the membrane 
permease and the ATPase, respectively.  Two membrane anchored heme-receptors, HtaA and 
HtaB, encoded by the hmu chromosomal locus were recently described and hypothesized to work 
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in conjunction with the HmuTUV transporter in heme acquisition and transport across the cell 
envelope [102].  Inside the Corynebacterium cytoplasm, a heme-oxygenase enzyme, HmuO, 
degrades the heme and releases the iron for use by the pathogen [73,103]. 
The heme uptake system studied in the most detail in Gram-positive bacteria is that from 
Staphylococcus aureus and is termed the Isd (iron-regulated surface determinants) system.  In the 
Isd system, the IsdA, B and H (HarA) proteins are covalently attached by the SrtA sortase 
enzyme to the cell wall, where they interact with a variety of ligands including heme, 
hemoglobin, hemoglobin-haptoglobin complex, fibrinogen, and fibronectin [104-107].  These 
proteins obtain heme and deliver it across the cell wall and the cell membrane in a cascade 
fashion via IsdC and the IsdEF ABC-transporter [82,83,108].  Unlike the surface exposed Isd 
receptors, IsdC is embedded deep in the cell wall by a dedicated sortase, SrtB [106,109,110].  
Ligand binding by IsdA, B, C, and H (HarA) is mediated by NEAT (Near transporter) domains, 
which are found in one or more copies in each of the receptor proteins.   
The NEAT domain is a protein motif first identified in 2002 that is encoded in variable 
copy number near ABC iron transporter genes in the chromosomes of several Gram-positive 
bacterial species [39].  It is approximately 125 amino acids long with low primary sequence 
homology and a predicted secondary structure of mostly β strands [39].  Expressed in 
recombinant form, the isolated NEAT domains of IsdA, IsdC, IsdH (HarA) and the second 
NEAT domain of IsdB (IsdBN2) have been studied and manifest different ligand preferences.  
The IsdA NEAT domain has fibrinogen binding ability [104] and binds heme [111].  The IsdC 
NEAT domain binds heme but not proteins such as hemoglobin, fibrinogen or fibronectin [112-
114].  The third NEAT domain of IsdH (IsdHN3) is also exclusively a heme-binding domain 
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[115,116] and IsdBN2 binds heme as well [117]. In contrast, the two N-terminal NEAT domains 
of IsdH (HarA) have demonstrated binding to hemoglobin and hemoglobin/haptoglobin, 
respectively [105,118,119].  Secreted or cell wall anchored NEAT proteins which are central to 
heme acquisition pathways were identified in other Gram-positive pathogens including Listeria 
monocytogenes [120], Bacillus anthracis, [121,122], and Bacillus cereus [123]. 
Heme uptake has also been studied in Group A Streptococcus, a β-hemolytic pathogen 
that uses host heme-containing proteins as an iron source [44].  One system involves a 10 gene 
iron-regulated operon that has been termed Sia (Streptococcal iron acquisition) [45].  Genes three 
through five in the cluster (siaABC or htsABC [53]) encode an ABC transporter that shares 
significant homology with heme or siderophore transporters found in other bacterial species [45].  
The second gene in the operon, shp, encodes a surface protein with β-sandwich fold similar to 
that of NEAT domains and is considered a distal member of the NEAT family [49].  Shp protein 
has been reported to bind heme at the cell surface and transfer it to SiaA (HtsA), the lipoprotein 
component of the ABC transporter [53]. The heme coordination of SiaA has recently been 
elucidated by further biophysical studies and is described as six-coordinate and low-spin, 
employing methionine and histidine as axial ligands [51]. The first gene in the sia operon 
encodes the Shr (streptococcal hemoprotein receptor) protein. Shr is a large (145kDa) 
hydrophilic protein that does not share significant overall homology with known heme or 
hemoprotein receptors [45]. The first studies of Shr revealed that it plays a role in iron 
acquisition.  It was observed to bind hemoglobin and hemoglobin-haptoglobin complex [45].  
The transfer of heme from Shr to the protein Shp has also been described [54].  Shr was recently 
demonstrated to bind the extracellular matrix proteins fibronectin and laminin, suggesting that it 
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also acts as an adhesin [48].  A null shr mutant is attenuated for virulence in a zebrafish model 
for necrotizing fasciitis, underscoring the importance of Shr to the infection process in vivo [48].    
Shr has two NEAT domains, but its overall domain architecture, which includes a unique 
N-terminal domain and a series of leucine-rich repeats, is different from any of the characterized 
heme and hemoprotein-binding receptors, including the NEAT-containing Isd proteins of S. 
aureus.  Shr also lacks a cell wall anchoring motif typical of the Isd receptor proteins of S. 
aureus; at the C terminus, Shr has a hydrophobic segment with a positively charged tail that 
threads the protein through to the cytoplasmic membrane.  It was recently demonstrated that Shr 
spans the cell wall and is exposed to the extracellular environment [48].  Shr is proposed to 
participate in the acquisition of heme by GAS and its delivery to Shp and/or the SiaABC 
transporter.  The uptake of heme from hemoproteins by Shr or its direct role in iron acquisition 
has not been shown, however.  In this study we establish the function of Shr in hemoglobin use 
and heme uptake by GAS. We analyze the functional domains of this receptor protein and 
present evidence that the mechanism of heme uptake by Shr is different from that of the 
characterized Isd proteins.  We suggest that Shr is a prototype of a new group of NEAT proteins 
involved in heme uptake. 
To distinguish between the two NEAT domains in Shr, the closest NEAT domain to the 
amino group will be referred to as NEAT1 and the second NEAT domain from the amino group 
will be referred to as NEAT2. 
 
 
15 
 
 
 
Results 1 
 
Shr is a composite NEAT protein found in pyogenic streptococci and C. novyi  
NEAT domains are key ligand-binding domains used by receptor proteins involved in 
heme acquisition and translocation in Gram-positive bacteria. We recently reported that the GAS 
Shr protein has two NEAT domains that are separated by an LRR region [48]. Additional 
sequence examination also identified an EF-hand motif between the first NEAT domain of Shr 
and the LRR segment (residues 532 and 544) and two copies of a short domain with unknown 
function, DUF1533 (residues 61-123 and 203-269) in the N- terminal region of Shr (Fig. 3).  In 
silico analysis using the web based SMART tool [124,125], reveals that there are about 160 
NEAT domains in 80 proteins encoded by Gram-positive bacteria from the Firmicutes phylum.  
Most of these NEAT-proteins are Isd-like molecules, which contain one or more copies of 
NEAT domains, a leader peptide, and in some cases a sortase recognition signal or other type of 
cell-wall binding region.  A few proteins consist of an LRR segment in addition to export signals 
and NEAT domain(s); these include the heme uptake protein of B. cereus, IlsA  [123], and the 
following hypothetical proteins A0PYT7 (C. novyi), O6HLL6 & O6HNR0 (B. thuringensis), and 
073BH4 (B. cereus).  Shr appears to be the first characterized protein with DUF1533 domains.  
An examination of the database demonstrated that DUF1533 is found in duplication in putative 
proteins with unknown function from the Clostridia class and in two species of Paenibacillus.  
Therefore, the domain architecture of Shr is different and more complex than most of the 
previously described NEAT receptors or the hypothetical NEAT-proteins found in bacterial 
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genomes.  The complex domain arrangement of Shr is intriguing and suggests that it evolved by 
joining several domains found separately in bacterial proteins of Firmicutes. Shr orthologues, 
which share identical or nearly identical domain architecture, are found in C. novyi as well as in 
the pyogenic streptococci S. equi zooepidemicus and S. dysgalactiae (Fig. 3).  A shr orthologue 
is found in the genome of S. equi subsp. equi as well; however, a frame shift mutation results in a 
truncated protein [126].  All streptococcal Shr orthologues are closely related in their primary 
amino acid sequence (58-86% identity) while the C. novyi orthologue shares fewer identical 
residues (~30%).  Intriguingly, the shr gene in all the streptococci is part of a 10-gene cluster 
which is homologous to the sia operon of GAS.  The shr gene in C. novyi on the other hand, is 
found in a genomic locus that encodes only a putative LRR-NEAT protein (A0PYT7).  Together 
these observations suggest that Shr may represent a new type of composite NEAT protein 
family. 
 
Shr obtains heme from solution and reduces ferric heme to ferrous heme   
Shr binding to hemoproteins in vitro and its genomic location in the sia operon together 
with the heme binding protein, Shp, and the SiaABC heme-transporter, suggest that Shr is 
involved in heme acquisition and transport by GAS [45]. This hypothesis was recently supported 
by the observation that purified Shr transfers heme to Shp [54]. The sequestering of heme from 
host proteins by Shr was not previously demonstrated, however, and the mechanism of heme and 
hemoprotein binding has not been investigated.  To characterize heme uptake by Shr, a histidine-
tagged recombinant protein (rShr) [45] was prepared and analyzed (Fig. 4A).  Shr is readily 
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reduced following treatment with dithionite or oxidized by ferricyanide, producing the 
corresponding absorption spectra with maxima around 410 nm for the bound ferric heme or 430, 
540 and 560 nm for the ferrous heme [54].  In this study we found that the spectral properties of 
rShr after ferricyanide treatment were almost identical to those without treatment, with Soret 
bands at 412 and 414 nm (Fig. 4B green and blue lines, respectively).  On the other hand, the 
addition of D, L-dithiothreitol (DTT) resulted in a shift in the absorption peak to 427 nm (Fig 4B 
red line) and the production of more resolved peaks at 536 and 566 nm, spectral characteristics 
of ferrous heme-protein complexes [127].  Therefore, our data indicate that rShr was purified 
from E. coli as mostly ferric heme complex. In the course of Shr purification, we observed that 
heme-bound rShr was considerably more stable than the heme-free protein, and that the addition 
of hemin to the E. coli culture prior to harvesting the cells resulted in a higher production of 
intact rShr.   
Heme binding by rShr was investigated further by monitoring the changes in the UV-
visible spectrum following the addition of increasing amounts of hemin (heme with ferric iron) 
to the protein solution.  The addition of free hemin resulted in a concomitant increase in rShr-
bound hemin, as was indicated by the growing absorbance at 414 nm (Fig. 4C).  Surprisingly, the 
UV-visible spectrum of rShr following the hemin addition also revealed growing absorption 
peaks at 427 and at 540 and 564 nm as well (Fig. 4C insert). Removing the free heme by dialysis 
did not lead to changes in the spectrum (data not shown). The growing peaks at 427, 540 and 564 
nm indicate a simultaneous increase in rShr-bound ferrous heme. The addition of hemin to rShr 
was done under aerobic conditions (using an open tube and vigorous mixing) and in the absence 
of reducing agents. Therefore, the observed rise in rShr-bound heme suggests that Shr reduces 
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the added hemin.  The addition of ferricyanide to the protein solution following titration with 20 
μM hemin resulted in a shift of the absorption peak from 427 back to 410 nm. The 410/280 
absorbance ratio that is indicative of the ferric heme load in Shr [54] was changed from 0.59 to 
0.75. Oxidation with ferricyanide also eliminated the peaks at 540 and 564 nm (Fig. 4D). 
Therefore, ferricyanide was able to oxidize the ferrous iron of the Shr bound heme, confirming 
that the changes in Shr spectrum seen following the addition of free hemin were due to a 
reversible reduction of the protein-bound hemin. It was previously reported that Shr could be 
purified from E. coli as a mixture of ferric and ferrous iron heme [54].  Our observations suggest 
that Shr has an inherent ability to reduce the ferric heme and to provide a stable environment for 
the produced ferrous complex. The autoreduction activity is a very intriguing characteristic of 
Shr. To the best of our knowledge, it is the first report of heme reduction by a bacterial heme 
receptor. 
 
NEAT1 and NEAT2 are both heme-binding domains in Shr 
Heme binding by the Isd proteins is imputable to their NEAT domains [128]. However 
some NEAT domains have been reported to not bind heme.  For example, IsdH NEAT3 domain 
binds heme [115-117], whereas IsdH NEAT1 and IsdH NEAT2 domains interact only with 
hemoglobin and haptoglobin [116].  Isd NEAT domains hold the heme within a hydrophobic 
pocket through several conserved residues including two invariant tyrosines, one of which 
coordinates the iron (Tyr 166 in IsdA) and a second residue (Tyr 170 in IsdA) that interacts with 
both the heme pyrrole ring and the coordinating tyrosine [111].  Sequence analysis revealed that 
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not all of the conserved residues in the Isd heme binding sites are found in Shr NEAT domains 
(Fig. S1); most significantly, both of the NEAT domains in Shr are missing the iron-coordinating 
residue Tyr 166, and only NEAT1 has the Tyr 170. Interestingly, the second heme binding 
protein coded by the sia operon, Shp, does not use tyrosine residues to coordinate the heme iron, 
and instead utilizes two methionines [49].  
To investigate heme acquisition by Shr, several recombinant proteins containing one or 
more of the component domains of Shr were constructed with an N-terminal fusion to the Strep-
Tag epitope. These Shr variants include recombinant proteins with the amino terminal domain of 
Shr (NTD) or the amino terminal domain through NEAT1 (NTD-N1), the NEAT1 domain, and 
the NEAT2 region (Fig. 5A). The recombinant proteins were overexpressed, purified by FPLC 
using a Strep-Tactin column, and analyzed. The protein containing only the NEAT1 region 
turned out to be highly insoluble and was therefore excluded from further investigations. SDS-
PAGE analysis confirmed the production and purification of the recombinant Shr protein 
fragments, revealing protein bands at the expected size for each construct: 61 kDa (NTD-N1), 42 
kDa (NTD), and 23 kDa (NEAT2, Fig 5B).  
The Shr protein variants that contained the first NEAT domain (NTD-N1) or the second 
NEAT domain (NEAT2) both had red color when purified and a UV-visible spectrum consistent 
with bound heme.  The purified NTD-N1 protein showed a significant absorbance at 410 nm 
indicating that it was co purified with ferric heme (Fig. 5C).  In contrast, the optical spectrum of 
the purified NTD fragment showed no band at the Soret region indicating that it did not contain 
heme (Fig. 5D). To test the heme binding ability by Shr’s N-terminal region, the recombinant 
NTD protein was incubated with increasing concentrations of hemin. The optical spectrum of the 
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protein after incubation showed no absorption at the Soret region. Instead, similar to the 
spectrum of free heme (Fig. S2), a broad peak at 390 nm was formed as increasing amounts of 
hemin were added, indicating an accumulation of unbound heme in the NTD protein solution 
(Fig. 5E). Therefore, the NEAT1 domain contained within the NTD-N1 protein is responsible for 
the ferric heme binding observed by this protein fragment.   
Unlike the ferric-heme load of the NTD-N1 protein, the optical spectrum of the purified 
NEAT2 protein suggests that it is purified with a mixture of ferric and ferrous heme. NEAT2 
spectra consistently had a significant Soret band at 428 nm along with sharp peaks at 535 nm and 
564 nm. However, variations in the intensity of absorbance at 410 and 428 nm (indicating 
different ratio of the protein bound ferrous and the ferric forms) were observed in the spectrum 
of NEAT2 from different protein preps (Fig. 5F and the blue line in Fig. S3). To further 
investigate heme binding by NEAT2, the protein was titrated with increasing concentrations of 
free hemin and the UV-visible spectrum was monitored (Fig. S3). As observed with the full 
length Shr, the addition of free hemin resulted in concomitant increase of absorption at around 
410 nm as well as 428, 535 and 564 nm.  NEAT2 was then treated with ferricyanide and the UV-
visible spectrum was taken after 5 and 30 min intervals and after 24 h. Within 5 min after 
addition of ferricyanide (Fig. 5G red line), the absorbance at ~410 nm increased compared to 
NEAT2 without ferricyanide (Fig. 5G blue line), and the bands at ~ 428, 535, 564 nm were 
almost gone, indicating that the NEAT2 protein was mostly in the oxidized form. The spectra did 
not change significantly at 30 min (data not shown). After 24 h (Fig. 5G green line), a red 
shoulder on the Soret band was seen, and the absorbance at 428, 535 and 564 nm had increased.  
Together these observations indicated that the NEAT2 protein autoreduced slowly.   
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Methemoglobin binding is mediated by the N-terminal domain of Shr, which specifically 
recognizes the holo form  
Following erythrocyte lysis, the α2β2 heterodimeric hemoglobin converts to 
methemoglobin, in which the heme is found in the ferric form. This is largely an αβ heterodimer 
[129,130]. Methemoglobin is likely to be a physiologically relevant heme source for the 
hemolytic GAS. To investigate Shr interactions with methemoglobin, we developed and used an 
ELISA.   rShr and the recombinant Shr fragments NTD-N1, NEAT2, and NTD, were used to 
coat the wells of microtiter plates and allowed to interact with increasing concentrations of 
methemoglobin (Fig. 6A). Ligand binding by the immobilized proteins was detected using 
hemoglobin antiserum. Wells coated with BSA and uncoated wells were used as controls for 
non-specific interactions.  rShr bound methemoglobin in a dose dependent and saturable manner, 
while only low background binding (OD 405 ≤ 0.1) of the hemoglobin antiserum to the control 
wells was observed.  The recombinant Shr fragments NTD and NTD-N1 bound methemoglobin 
with binding profiles that were similar to the full length Shr, and methemoglobin binding 
appeared saturated at a concentration of 10 nM (Fig. 6A). The observation that the full length 
Shr, NTD-N1 and NTD alone equivalently bind methemoglobin indicates a preponderant role for 
the NTD in hemoglobin binding.  In contrast, no methemoglobin binding by the NEAT2 protein 
was detected. Therefore, unlike IsdA, IsdB, and IsdH proteins, which use NEAT domains to bind 
hemoglobin, an uncharacterized protein pattern found in the N-terminal domain of Shr interacts 
with hemoglobin.  
We hypothesize that Shr interacts with methemoglobin to acquire heme from the host.  
We therefore asked whether Shr could differentiate between the apo and the holo forms of 
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hemoglobin.  Heme was removed from methemoglobin according to Asakura et al, [131] and the 
formation of the apoprotein was confirmed by the UV-visible spectrum, which revealed no 
absorption at the Soret region. The binding of NTD to immobilized apohemoglobin was tested 
by ELISA.  In contrast to its interactions with holoprotein, no binding of NTD to apohemoglobin 
was observed (Fig. 6A, red line). Similar to the NTD, the full length Shr did not bind 
apohemoglobin (Fig. S4). A control ELISA performed with immobilized holo and 
apohemoglobin demonstrated that the hemoglobin-specific antibody was able to detect both 
forms of hemoglobin similarly over the range of hemoglobin concentrations studied (Fig. 6B).  
Therefore, the absence of binding of apohemoglobin in the experimental ELISA shown in Fig. 
6A (red line) was not due to a lack of ability of the hemoglobin antiserum to recognize the 
apoprotein. In conclusion, these experiments demonstrate that Shr differentiates between the 
holo and the apo forms of hemoglobin and binds only to heme-loaded protein.  
 
The NEAT 2 domain in Shr mediates most of its binding to ECM 
We have recently observed that in addition to its interactions with hemoproteins, Shr also 
functions as an adhesin and binds fibronectin and laminin [48]. To determine the domains 
involved in the ability of Shr to bind these proteins components of the extracellular matrix 
(ECM), immobilized rShr, NTD, NTD-N1, and NEAT2 were allowed to react with the ECM 
components using ELISAs. Ligand binding was detected with antibodies specific for fibronectin 
or laminin. When fibronectin was added in increasing concentrations to the immobilized 
proteins, rShr as well as the recombinant fragments NTD-N1 and NEAT2 bound it in a 
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concentration-dependent and saturable manner (Fig. 7A). The NEAT2 protein demonstrated the 
highest binding to fibronectin, while only low level binding was seen with NTD-N1. No 
interactions with fibronectin were demonstrated by the immobilized NTD protein. These 
observations suggest that NEAT regions mediate the observed Shr binding to fibronectin.  
Similar observations were made with laminin; as shown on Fig. 7B, rShr, and NEAT2 proteins 
bound laminin, while no significant binding to laminin was observed by the NTD or NTD-N1. 
Together, these observations indicate that while both Shr NEAT domains are able to interact 
with some ECM components, the NEAT2 domain plays a more significant role in this activity of 
Shr.  
 
The NTD-NEAT 1 region of Shr is sufficient for heme acquisition from methemoglobin 
We next asked if the NTD-N1 fragment of Shr, which contains the hemoglobin-binding 
region and the heme-binding NEAT1, is sufficient for heme acquisition from methemoglobin.  
Heme was removed from the purified NTD-N1  [131], and the formation of apo NTD-N1 was 
confirmed by UV-visible spectrum analysis (Fig. 8A). The heme transfer assay was done over a 
Strep-Tactin column with immobilized apoNTD-N1 protein. Methemoglobin in equimolar 
amounts to the immobilized apoNTD-N1 protein was flowed through the column. The bound 
hemoglobin was removed by extensive washes with salt containing buffer (see Materials and 
Methods), and the NTD-N1 protein was then eluted with desthiobiotin.  Western blot analysis of 
the fractions collected during this procedure revealed that the hemoglobin containing fractions 
also included low amounts of NTD-N1 in addition to methemoglobin (lane 3, Fig. 8B), 
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suggesting that some methemoglobin/NTD-N1 complexes were washed from the column. The 
NTD-N1 fraction that was eluted with desthiobiotin, however, did not contain a detectable 
amount of hemoglobin (lane 4, Fig. 8B). The optical absorbance of NTD-N1 after the 
methemoglobin passage showed a sharp peak at 411 nm, indicating that the apoNTD-N1 
acquired heme from methemoglobin (red line, Fig. 8A). To confirm that the observed absorbance 
at 411 nm resulted from NTD-N1/heme complex and not from trace amounts of methemoglobin, 
we analyzed the absorbance of 0.7 μM methemoglobin solution, a concentration which is above 
the detection level of the hemoglobin antibody utilized in the assay (lane 6, Fig. 8B). This 
analysis revealed that methemoglobin, at the tested concentration, had a significantly lower Soret 
band than in the NTD-N1 fraction.  
A similar experiment was done with immobilized NTD-N1 with hemin chloride solution 
(in 4-fold molar excess) instead of methemoglobin in the mobile phase. The optical analysis of 
NTD-NEAT1 after passage of free hemin also revealed that it acquired heme as indicated by the 
peak at 412 nm (blue line Fig. 8A).  However the peak at the Soret region of NTD-N1 after the 
passage of methemoglobin was significantly higher than that after contact with the hemin 
chloride solution.  This observation suggests that the NTD-N1 protein acquires more heme from 
hemoglobin than from the hemin solution, supporting heme transfer from methemoglobin 
directly to the immobilized NTD-N1. Heme acquisition by apoNTD-N1 was also investigated 
using an alternative assay in which the NTD-N1 was allowed to interact with methemoglobin in 
solution at room temperature. The UV-visible spectrum of the NTD-N1 protein after its 
separation from methemoglobin (using Strep-Tactin column) revealed a sharp peak at 410 nm 
(Fig. S5), demonstrating heme transport from methemoglobin to the NTD-N1 protein.  
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Interestingly, the absorption intensity at the Soret region following 5 min of co-incubation was 
about 80% of that seen following 75 min, indicating rapid heme sequestering by the NTD-N1 
protein. 
 
Shr is required for GAS growth using hemoglobin as the sole iron source  
To determine the importance of the heme binding domains to the function of Shr in vivo, 
several GAS mutants containing in frame deletions of various regions in shr were constructed.  
These include a mutant with NEAT1 deletion mutant (ΔNEAT1), a mutant with a deletion that 
spans the distal part of the LRR and most of the second NEAT domain (ΔNEAT2), and a mutant 
with a large deletion that includes both NEAT domains and the region in between (ΔNEAT1-2, 
Fig. 9A).  The production of shr alleles in the expected size in the genome of each of the mutants 
and of the corresponding Shr proteins was confirmed by PCR and Western blot analyses (Fig. 9B 
and 9C).  This analysis also confirmed the production of the wild type Shr when the ΔNEAT1-2 
was complemented. Successful complementation of the null shr mutant was previously shown 
[48]. RT-PCR analysis with primers specific for siaA, which is located downstream of shr, 
verified that the shr mutations were not polar and did not affect the expression of the 
downstream genes in the sia operon (Fig. 9B). 
The ability of wild type, a shr null mutant [48], and the isogenic mutant strains described 
above to use hemoglobin as a sole source of iron was investigated using a growth assay that is 
based on iron-depleted chemically defined medium (CDM). The wt strain and all of the shr 
mutants grew well in complete CDM medium containing 20 μM of free iron (Fig. 9D).  On the 
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other hand, CDM that was prepared without iron and contained 2 mM of the ferric chelator 2, 2-
dipyridyl did not support significant growth of any of the tested GAS strains (Fig. 9E).  The 
addition of 20 μM of methemoglobin to the iron-depleted CDM restored growth of the wt strain 
to the level obtained with CDM containing 20 μM iron (Fig. 9F), lower hemoglobin 
concentration however, did not support growth of any of the strains in the iron depleted medium 
(Fig. S6 A & B). These observations demonstrate that iron is indeed the limiting factor for GAS 
growth in the 2,2-dipyridyl CDM and that GAS is able to use hemoglobin to satisfy its iron needs 
as we previously reported [44]. No significant growth differences were observed between the shr 
mutants containing a deletion of NEAT1 (ΔNEAT1) or of NEAT2 (ΔNEAT2) and the wt strain 
in the 2, 2-dipyridyl-CDM supplemented with methemoglobin. Therefore, the ΔNEAT1 and the 
ΔNEAT2 shr mutants are not affected in their ability to use hemoglobin as a source of iron.  On 
the other hand, the growth of the shr null mutant and to a lesser extent that of the mutant that was 
missing both of the NEAT domains (ΔNEAT1-2) was impaired (Fig. 9F).  The growth phenotype 
demonstrated by the shr mutants was reversed by complementation with the shr gene (Fig. 9G).  
These findings establish that Shr is required for hemoglobin utilization in vivo and suggest that 
Shr function requires at least one of the heme binding NEAT domains. The addition of 
methemoglobin in higher concentration (60 μM) supported better growth of the tested GAS 
strains (Fig. S6C).  Thus, the Shr-dependent pathway for hemoglobin utilization in GAS may be 
of high affinity.  However, additional pathways for acquisition of iron from hemoglobin also 
exist, as previous findings suggest [46]. 
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Discussion 1 
During the infection process, the β-hemolytic GAS can tap into the intracellular heme 
reservoir due to the potent hemolysins it produces and satisfy its needs for iron with hemoglobin, 
hemoglobin-haptoglobin, and other heme-containing proteins [44,132]. Previous observations 
implicated the surface-exposed NEAT protein, Shr, in the first step of heme acquisition from 
host proteins by GAS [45,54].  In this work we have provided the first direct support for this 
proposition by demonstrating that Shr can obtain heme from methemoglobin and by establishing 
that Shr function is important for GAS ability to use methemoglobin as an iron source.  GAS use 
of Shr in heme acquisition is reminiscent of NEAT-containing receptors such as the Isd proteins 
in S. aureus and related proteins from other Gram-positive bacteria.  In this study, however, we 
demonstrate that GAS Shr structure and function are different from that of previously 
characterized NEAT proteins and suggest that Shr represents a new type of protein family with a 
different mode of hemoglobin binding and heme acquisition. 
 
Shr represents a family of composite NEAT proteins   
Shr is a complex NEAT protein that consists of a unique combination of domains and 
protein motifs (Fig. 3).  The database contains many secreted or surface proteins with NEAT 
domain(s); a few also carry LRR region(s) including IlsA of B. cereus [123]. LRR are commonly 
involved in protein recognition and protein-protein interactions [133].  It is possible that the LRR 
may help facilitate the intra-molecular communications that are likely to take place in Shr or its 
interactions with the other transport components such as Shp.  DUF1533 is a domain of unknown 
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function found in hypothetical proteins that contain secretion or export signals and sometimes 
other functional regions including LRR.  The combination of two DUF1533, a LRR region and 
two NEAT domains is seen for the first time in Shr, however.  Interestingly, Shr seems to be the 
first characterized NEAT protein that has an EF-hand motif (located between the NEAT1 and the 
LRR regions, Fig. 3).  The EF-hand motif is a calcium-binding domain that is ubiquitous among 
eukaryotic calcium-binding proteins such as calmodulin, but is also found in bacterial sequences 
[134-136].  As with other bacterial proteins with EF-hands, the functional significance of this 
motif is yet to be determined. Further in silico analysis identified several orthologues of Shr in C. 
novyi, S. equi sub spp zooepidemicus, S. equi sub spp equi, and S. dysgalactiae. These Shr-like 
proteins share with Shr significant sequence homology and domain architecture, suggesting that 
GAS Shr is a representative of a small family of NEAT proteins that evolved by combining 
domains found in surface or secreted proteins encoded by bacteria from Phylum Firmicutes.   
 
Shr is the only NEAT protein to show ferric heme reduction 
We isolated rShr with ferric heme (Fig 4B), indicating that this protein can sequester 
heme from E. coli.  It was previously reported that Shr could be isolated from E. coli apoprotein 
with a mixture of ferric and ferrous heme [54].  When we titrated the protein with free hemin, the 
increase in the absorption around 414 nm demonstrated that Shr can also acquire ferric heme 
from solution (Fig. 4C).  The concurrent rise in absorption at 427, 540 and 564 nm indicated 
increasing amounts of rShr-bound ferrous heme and was reversed by oxidation (by ferricyanide, 
Fig. 4D). This increase in bound ferrous heme following the addition of ferric heme to the 
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purified rShr strongly suggests that Shr autoreduces the heme, even in air.  Shr clearly provides a 
stable environment for the bound ferrous heme. This is the first demonstration that Shr can 
obtain heme from solution and reduce it to ferrous heme.  Heme reduction is a unique property of 
Shr that to our knowledge has not been reported for any other NEAT protein.   
The iron oxidation state in protein-bound heme can have a significant impact on the heme 
fate and its environment.  For example, reduction of the ferric heme in IsdC NEAT domain 
results in the loss of the heme from the protein [112]. On the other hand, the full length IsdA and 
its single NEAT domain can bind both ferric and ferrous heme. The reduction to ferrous heme, 
however, changes the iron axial ligand from tyrosine to histidine and renders it accessible to 
small anionic ligands such as CO. Based on these observations, it is suggested that iron 
oxidation/reduction lead to subsequent conformational changes with closing/opening of the 
heme-binding pocket in IsdA [112,137]. Our in vitro study of rShr shows that the full-length 
protein is able to bind the heme group in both the ferric and the ferrous forms as well. It seems 
possible that, as in IsdA however, iron oxidation/reduction may be accompanied by structural 
changes that influence the heme location within the protein (i.e., binding to first or the second 
NEAT domain) or the subsequent in vivo steps in the heme trafficking such as the heme transfer 
to Shp or SiaA.   
 
 
 
30 
 
 
 
Functional and sequence analysis show that both NEAT domains in Shr are divergent from 
one another and from the NEAT domains of the Isd protein family   
The optical spectrum of the Shr variants NTD-N1 and NEAT2 demonstrate that they both 
complex heme, while the NTD protein, in contrast, did not show any heme binding.  Sequence 
alignment demonstrated that only a few of the residues that contact the heme in Isd NEAT 
domains are conserved in the putative heme biding sites of NEAT1 and NEAT2 in Shr [128], 
(Fig. S1).  Most noticeably, both of the NEAT domains in Shr are missing the potential iron-
coordinating residue, Tyr 166, a heme ligand in other NEAT proteins, and only NEAT1 has Tyr 
170 (proposed to regulate heme binding and release) (Fig. S1). Therefore, the heme-binding 
region in both Shr NEAT domains is quite different from that of Isd-like heme-binding NEAT 
domains and the heme iron may not be coordinated by a tyrosine, at least in the NEAT2 domain 
of Shr. These observations suggest that Shr NEAT domains have different mechanism for 
interactions with heme. Likewise, Shp, which can acquire heme from Shr, has a unique iron 
coordination involving two methionines within the single Shp molecule that function as axial 
ligands [49]. Additional work is needed to determine the heme axial ligands of the NEAT 
domains in Shr. Future investigations of the evolutionary relation between Shr NEAT domains 
and Shp, which represents a more remote member of the NEAT family, are warranted. 
Both of the NEAT domains in Shr bind heme. The optical spectra of NTD-N1 and 
NEAT2 proteins as isolated from E. coli indicate that NEAT1 is complexed with ferric heme, 
and that NEAT2 is bound to both ferric and ferrous heme (Fig. 5C and 5F).  Like with the full-
length Shr, titration of NEAT2 with increasing concentration of hemin resulted in raising 
amounts of bound ferric and ferrous heme (Fig. S3).  Over time some of the ferric heme in 
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NEAT2 (produced by oxidation with ferricyanide) was reduced to ferrous heme (Fig. 5G).  
Together these observations suggest that the NEAT2 domain in Shr is capable of autoreduction. 
Functional differences between NEAT1 and NEAT2 were also found in their interaction with 
non-heme ligands.  While Shr NEAT2 interacts with both fibronectin and laminin molecules, 
NEAT1 binding to fibronectin is significantly weaker and it does not demonstrate significant 
binding to laminin (Fig. 7).   
 
A unique site in Shr N-terminal region mediates binding to methemoglobin   
We demonstrated in this study, using ELISA with immobilized Shr variants, that the full-
length rShr, the NTD, and the NTD-N1 all bound methemoglobin similarly. The NEAT2 protein, 
on the other hand, did not interact with methemoglobin (Fig. 6A).  Therefore, it appears that an 
unspecified region within Shr NTD mediates its binding to methemoglobin. While this 
manuscript was in preparation Meehan et al [138] reported that like GAS NTD, the truncated Shr 
molecule produced by S. equi sub spp equi (consisting mostly of Shr NTD) binds hemoglobin 
and hemoglobin-haptoglobin complex. The finding that the interaction of Shr with 
methemoglobin is not mediated by NEAT domains distinguishes Shr from the previously studied 
Isd receptors. Domain analysis of IsdA and IsdH demonstrated that binding to host hemoproteins 
is carried out by the single NEAT domain in IsdA and two of the NEAT domains of IsdH 
[104,116]. Site directed mutagenesis localized the binding to a conserved aromatic motif also 
found in the first NEAT domain of the IsdB [116], which binds hemoglobin and 
hemoglobin/heptoglobin complex [107]. Consistent with the results of the ELISA experiments, 
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both of the Shr NEAT domains are missing the hemoglobin binding sites identified in the Isd 
proteins. Additional work is required to identify the region within Shr NTD that is involved in 
hemoglobin binding. The sequence of the Shr N-terminal region is unique, and besides the two 
copies of DUF1533, it shares sequence homology only with Shr orthologues. Therefore, 
hemoglobin binding is mediated by a new protein motif in Shr. 
Hemoglobin binding by bacterial receptors is not fully understood.  In this work we show 
that the Shr N-terminal domain binds only heme-containing hemoglobin (Fig. 6A). The 
functional significance of this observation is that Shr may release the bound hemoglobin after 
sequestering all the heme. It is not clear how Shr differentiates between the apo and the holo 
forms of methemoglobin. Recognition of the heme moiety does not seem to be part of Shr 
binding to methemoglobin as NTD does not bind heme and the heme is mostly buried within 
hemoglobin [139]. We hypothesize, therefore, that Shr recognizes a tertiary structure in the 
holoprotein that is disrupted when heme is lost, rather than recognizing a linear region within the 
α or β polypeptides of hemoglobin.  
 
The NTD and NEAT1 in Shr are sufficient for heme acquisition from methemoglobin in vitro 
It was previously demonstrated that purified Shr transfers heme directly to apoShp in 
vitro [54], while the direct movement of heme from methemoglobin to Shp was not observed. 
Therefore it was hypothesized that Shr is involved in the first step of heme sequestering from 
hemoglobin.  In this study we used the column-immobilized apoNTD-N1 to ask if it could obtain 
heme following transient interactions with methemoglobin or free heme (Fig. 8). Spectral 
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analysis done with NTD-N1 following the passage of methemoglobin showed that it obtained 
heme. In a separate assay, co-incubation of apoNTD-N1 with methemoglobin in solution 
demonstrated that the heme transfer from methemoglobin is fast. NTD-N1 was also able to 
receive heme from solution, but to a lesser extent. These experiments imply that heme is 
transfered directly from methemoglobin to the NTD-N1 protein. Further investigations are 
required to determine if NEAT2 can obtain heme from NEAT1 and/or from methemoglobin, and 
to find out which of the Shr domains are required for the subsequent step in heme trafficking.   
 
Shr is needed for heme uptake from methemoglobin in vivo   
The growth of the shr- and ΔNEAT1-2 mutants in iron-depleted medium supplemented 
with hemoglobin was impaired in comparison to that of the wild type GAS strain (Fig 9F).  The 
mutant growth phenotypes were reversed by complementation with the shr gene, establishing the 
role of Shr in hemoglobin utilization in vivo.  The residual growth of the ΔNEAT1-2 in low 
hemoglobin concentration and the full growth of both mutants observed when higher amounts of 
hemoglobin were added (Fig. S6C) are consistent with a previous report suggesting that 
additional hemoglobin utilization pathways are found in GAS [46].  Since the shr mutants 
required a high concentration of hemoglobin to restore growth than the wild type strain, we 
suggest that Shr mediates a high affinity pathway.  It is noteworthy, however, that the deletion of 
a single NEAT domain (as in the ΔNEAT 1 and ΔNEAT 2 mutants) did not have significant 
growth defect.  These findings indicate that either one of the NEAT domains is sufficient for 
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heme uptake from hemoglobin in vivo, suggesting that despite the differences found between Shr 
NEAT domains, they have some functional redundancy.   
In conclusion, this study establishes the role of Shr in heme acquisition from hemoglobin, 
and demonstrates that the streptococcal receptor is a representative of a structurally and 
functionally distinct NEAT protein family found in C. novyi and pyogenic streptococci. We have 
begun to elucidate the functional domains of Shr, although additional investigations are required 
to fully understand the mechanism of heme uptake mediated by this intriguing protein. 
 
Materials and methods 1 
 
Strains, media, and growth conditions 
Escherichia coli (E. coli) DH5α and XL1 blue were used for cloning and gene expression.  The 
GAS strain used in this study was NZ131, an M type 49; ZE4912 an isogenic strain with a non 
polar, null mutation in shr (shr::aad9) [48]; ZE4924, a merodiploid strain, which contains both 
the shr::aad9 and the wild type alleles of shr in the chromosome [48].  E. coli cells were grown 
aerobically in Luria Bertani (LB) medium at 37 ºC.  GAS cells were grown statically at 37 ºC in 
Todd-Hewitt broth with 0.2% w/v yeast extract (THY, Difco Laboratories) or Chemically 
Defined Medium (CDM; SAFC Biosciences) as described in Montañez et al 2005 [46]. When 
necessary, 100 µg/ml ampicillin, 100 μg/ml spectinomycin, 70 or 300 μg/ml kanamycin (for E. 
coli and GAS respectively) was added to the medium. 
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DNA manipulations 
Chromosomal and plasmid DNA extraction and DNA manipulations, including 
restriction digest, cloning, and DNA transformation into E. coli or GAS, were done according to 
the manufacturer’s recommendations and with standard protocols as previously described 
[140,141]. PCR for cloning was performed using the High Fidelity AccuTaq LA DNA 
Polymerase (Sigma). PCR products were purified with the QIAquick PCR Purification Kit 
(Qiagen). DNA ligation was done with using Fastlink ligation kit (Epicentre).  For RNA 
extraction and analysis, GAS cells were harvested at the logarithmic growth phase and total 
RNA was prepared using the RiboPure-Bacteria Kit (Ambion).  RNA was quantified 
spectrophotometrically, and its integrity was examined by agarose gel electrophoresis.  For RT-
PCR cDNA was produced by Superscript III reverse transcriptase (Invitrogen) according to the 
manufacturer’s specification. The oligonucleotide primers used in this study are listed in Table 
S1. Table S2 lists and describes the construction of the plasmids used in this work. 
 
Strain construction 
The following isogenic mutant series was constructed in NZ131 background: ZE4925 (in 
frame deletion of NEAT1 in shr, ΔNEAT1), ZE4926 (in frame deletion of the LRR 3’ and most 
of the NEAT2 in shr, ΔNEAT2), and ZE4929 (in frame deletion of the region between NEAT1 
up to and including NEAT2 in shr, ΔNEAT1-2).  Alleles with unmarked and in frame deletions 
in the shr gene with about 1 Kb of flanking sequence were cloned into the temperature sensitive 
shuttle vector pJRS700, as described in Table S2. The mutations were then introduced into GAS 
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chromosome by transforming NZ131 cells with each of the recombinant vectors and selecting for 
Kanamycin resistance at 30 °C. The transformants were then passed in antibiotic free medium at 
37 °C. Mutants in shr gene, generated by allelic replacement via double homologous 
recombination were identified by screening for plasmid loss (kanamycin sensitivity). The 
formation of each mutation was confirmed by PCR and Western blot analysis (Fig. S5).  The 
GAS strains ZE4925, ZE4926, and ZE4929 were engineered using plasmids pXL2, pXL13, and 
pXL3 respectively. The strain ZE4935 is a merodiploid containing both the wt and the ΔNEAT1-
2 shr alleles in the chromosome. For ZE4935 construction, the temperature sensitive plasmid 
pXL14 was introduced into ZE4929 cells and vector integration into the chromosome (via 
homologous recombination) was selected on Kanamycin at 37 °C; strain construction was 
confirmed by PCR and Western blot analysis (Fig. S5 and data not shown). 
 
Overexpression and Purification of Recombinant Shr, NTD, and NTD-N1 and NEAT2 
The expression of Strep-tag Shr (pEB2), Strep-tag Shr NTD (pEB10), Strep-tag NTD-N1 
(pEB11), or Strep-tag NEAT2 (pHSL2) was induced with 200 ng/ml anhydrotetracycline, 
overnight at 27 ºC.  Cells were harvested, resuspended in lysis buffer (100 mM Tris/HCl pH 8, 
500 mM sucrose, 1 mM EDTA) with the addition of 0.5 mg/ml lysozyme, β-D glucopyranoside 
final concentration 0.5% and Complete, mini-EDTA-free protease inhibitor cocktail tablets 
(Roche) then lysed by sonication. The cells pellet was centrifuged and the cleared lysate was 
then applied to a Strep-Tactin Superflow column (IBA) with a 5 ml bed volume and purified 
using FPLC. A step gradient program was used and Strep-tag proteins were eluted with 5 column 
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volumes of 100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin.  A 
cation exchange column (4 ml bed volume Hi-trap SP HP, GE Healthcare) was used for further 
purification of Strep-tag Shr by FPLC. The Strep-tag Shr directly after elution from the Strep-
Tactin Superflow column was diluted 1:5 in 50 mM acetic acid pH 4.8, applied to the Hi-trap SP 
HP column and eluted with 50 mM acetic acid pH 4.8 plus 1M NaCl2.  
His-tagged Shr was expressed (pCB1) and purified as described previously [48]  with the 
following exceptions:   when necessary, hemin in dimethyl sulfoxide was added to give a final 
concentration of 1 µM hemin in the cell culture one hour before cell disruption by sonication and 
sonication was increased to include ten cycles. 
All proteins were prepared in Laemmli sample buffer and separated by sodium dodecyl 
sulfate-10% polyacrylamide gel electrophoresis (SDS-10%). Western Blot analysis was 
performed with polyclonal antibodies against Shr raised in rabbit as described previously [45]. 
Total protein concentration was measured using a Lowry assay (Pierce Biotechnology, Inc). 
Each elution fraction was stored in 15% glycerol with 200 µl protease inhibitor cocktail 
(Complete, mini-EDTA-free, Roche). Fractions used for further study underwent buffer 
exchange to 20 mM Tris-HCl, 15% Glycerol, pH 8.0 and were stored at -20 °C. 
 
Enzyme-linked Immunoabsorbent Assays (ELISA) 
An enzyme-linked immunoabsorbent assay (ELISA) was used to analyze the ability of 
Strep-tagged Shr, NTD, NTD-N1 and NEAT2 to bind to various ligands. ELISA plate wells 
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(Costar, Corning, inc.) were coated with a 50 µl solution containing the desired concentrations of 
bait proteins. Wells coated with BSA and uncoated wells were used as controls for non-specific 
interactions. The bait proteins were diluted in PBS buffer (10 mM phosphate-buffered saline, 
100 nM NaCl, pH 7.4) and included rShr, NTD, NTD-N1, NEAT2 and BSA. After the bait 
proteins were incubated overnight at 4 ºC, the wells were washed with PBS-Tween (0.05%) 
buffer and blocked with 200 µl 5% soy infant formula (Nestle)-PBS-Tween for 1 hour at 37 ºC 
then washed again to remove blocking solution.  For apohemoglobin preparation, heme was 
removed from methemoglobin according to Asakura et al. [131]. The desired concentrations of 
human apo/holomethemoglobin (Sigma), human fibronectin (BD) or mouse laminin (BD) in 5% 
soy/PBS-Tween were then added to each well (50 µl / well). The wells were then washed PBS-
Tween/well to remove unbound protein.  Fifty µl of a 1:15,000 dilution of polyclonal rabbit anti-
hemoglobin (sigma), rabbit anti-fibronectin (abcam) or rabbit anti-laminin (abcam) antibodies in 
blocking buffer were subsequently added to each well and incubated at 37 ºC for one hour, and 
the wells were then washed. Fifty µl of goat anti-rabbit IgG conjugated to alkaline phosphatase 
(Sigma) at 1:6000 dilution in blocking buffer was added to each well and incubated at 37 ºC for 
1h.  Interactions between recombinant Shr, NTD, NTD-N1 or NEAT2 and the ligands were then 
detected by adding pNPP substrate and developing the chromogenic reaction (KPN). Plates were 
read at 405 nm on an automated ELISA reader for intervals up to one hour after development. 
An assay to assess the ability of a variety of blocking buffers to diminish nonspecific binding 
was also performed as described above except the ELISA wells were uncoated.    
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rShr, NTD, NTD-N1 and N2 UV-visible spectra 
The spectrophotometric analysis of samples from 250 to 700 nm was carried out using a 
Varian Cary 50 Bio spectrophotometer. Absorption spectra of the purified proteins were 
measured on the spectrophotometer in a quartz cell with an optical path length of 10 mm. All 
absorption spectra shown in this study are representative of multiple experiments done with at 
least three biological replicas. 
 
Heme titration assays 
A stock solution of hemin chloride in DMSO was prepared. The absorbance of a 1:1000 
dilution of the stock solution at 404 nm was recorded and the concentration of hemin chloride in 
the stock solution was calculated using Beer’s law (A= εbc where hemin in DMSO ε404=188,000 
m-1cm-1 [142,143]. Protein samples were diluted in Strep-tag elution buffer to 3 μM. Absorbance 
from 250-700 nm was recorded before addition of hemin chloride. Hemin chloride was added to 
1 ml aliquots of 3 μM protein to a final hemin chloride concentration of 1 μM, incubated with 
stirring at 4° C for 1 h and the absorbance from 250-700 nm was scanned and recorded. This was 
repeated for hemin chloride concentrations of 3 µM, 5 µM, 10 µM and 20 µM. Strep-tag elution 
buffer alone was similarly incubated with 1 µM, 3 µM, 5 µM, 10 µM and 20 µM of hemin 
chloride. These heme-containing buffer solutions were scanned as blanks for the UV-visible 
spectra of the protein solution containing corresponding concentrations of hemin chloride. The 
total volume of DMSO added to the protein solutions or the blank solutions ranged from 0.15 µl 
to 3 µl. Thus, the final DMSO concentration in the sample was 1.5x10-4 to 3x10-3 v/v. 
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Ferricyanide and DTT treatment were done in sealed tubes with incubation at room temperature. 
Ferricyanide was then removed by dialysis.  
 
Heme transfer from methemoglobin 
Heme transfer from methemoglobin to Shr fragment NTD-N1 was done using FPLC. 
ApoNTD-NEAT1 was prepared according to the method described by Asakura et al [131] and 
100 nmoles of the protein in 2 ml Strep-tag wash buffer were attached to a Strep-Tactin 
Superflow column. Equivalent moles of methemoglobin (100 nmoles) were flowed through the 
immobilized NTD-N1. The bound methemoglobin was removed by washing several times (10 
column volumes) with a wash buffer (100 mM Tris-HCl pH 8.0, 250 mM NaCl, 1 mM EDTA). 
Subsequently, the immobilized NTD-N1 was eluted with Strep-tag elution buffer (100 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin).  Methemoglobin flow-through 
and NTD-N1 elution samples were collected and analyzed by Western blot using anti-Shr and 
anti-hemoglobin antibodies. Protein concentration in the different fractions was determined by 
Modified Lowry assay, and Spectroscopic analysis (250 - 700 nm) of 10 μΜ apoNTD-N1 before 
and after passage of methemoglobin, was carried out using a Varian Cary 50 Bio 
spectrophotometer.    
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Culture in microplate 
All GAS strains were grown in CDM supplemented with 3 mM of L-cysteine, 15 mM of 
sodium bicarbonate, 2.5 mM of magnesium sulfate, 44 μM of calcium chloride, 15 μM of zinc 
chloride, 20 μM of manganese and either 20 μM of metal iron or a range of concentrations of 
human hemoglobin. In the latter case, 2 mM of 2, 2-dipyridyl was added to the supplemented 
CDM to completely chelate residual metal iron prior to the addition of Hb. The prepared media 
were inoculated to final OD600 = 0.005. The inocula consisted of cells grown overnight at 37 °C 
on blood agar and suspended in iron-free CDM.  Bacterial suspensions at OD600 = 0.5 were 
diluted 1:100 into the corresponding medium, which was then dispensed in 200 μl triplicates in a 
96 well microplate (Costar 3595, Corning Inc.) at 37 °C for 24 h. The experiments were 
performed in triplicates and were done at least twice for each strain.  Kanamycin (150 μg/ml) 
was added to the medium for the growth of the complemented strain ZE4924 and ZE4935. 
 
In silico analysis 
The following accession numbers were utilized for the NEAT domain-containing proteins 
examined in this study:  S. aureus IsdA ABX29083, S. aureus IsdC ABX29084, S. aureus IsdB 
YP_001332074, S. aureus IsdH Q6G8J7, S. equi subs. zooepidemicus YP_002122760, C. novyi 
NT YP_877540, S. dysgalactiae subs. equisimilis YP_002997560, S. pyogenes Shr MGAS5005  
ABW80932.  Identification of all protein domains was conducted by SMART analysis except the 
EF-hand domain, which was identified by PROSITE. Multiple sequence alignment the NEAT 
domains were executed using the ClustalW program.   
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Table 1: Primers used in this study 
Name Sequence Source 
204A-FW 5’-GCTATGATGCTGTTAAGCGTGTGG siaA 
204A-Rev 5’-TCTGGAATGGCATGAGCTGTTC siaA 
Y-His-Fwd 5’-CCCCGAATTCAAATCACAAGAGCCTTTAGT shr 
Strep-shr-rev     5’-CCCCTCGAGTTATTTAAATAATGTCTTTGCACC shr 
ZE1 5’-CCCCGAATTCAAATCACAAGAGCCTTTAGTT shr 
ZE58 5’-ATCCCTCGAGGTCGACCTGCAGG shr 
ZE59 5’-CCCCTCGAGAACCTCACCTGCTTGATAAGAC shr 
ZE60 5’-TTTCTCGAGCCCAACCCCTTTTTCTTTATCATCAG shr 
ZE50 5’-AAAGGATCCACTGATGATAAAGAAAAAGGG shr 
ZE51 5’-AAAGGATCCAACCTCACCCTGCTTGATAAG shr 
ZE139 5’-CCCCGAATTCTTAAATCAAAAACAATTGCGTG shr 
ZE106 5’-TTGTAGAGGAATTCTTTTATCAGAGATATCCTC’ shr 
ZE126 5’-GTAACCTTTGTGATTTGCTGAG’ shr 
ZE140 5’-AAAAGGTACCTTAGACAACCTTTGCCTTCTCTG shr 
ZE168 5’- CCCCCCATCGATTCACAAGAGCCTTTAGTTCAGTCAC shr
ZE169 5’-CCCCCCATCGATCTTATTTAAATAATGTCTTTGCACC shr
ZE170 5’-TTTTTTATCGATTTAGCTCTTGCTGACTAG shr
ZE171 5’-TTTTTTATCGATGGAAGCTTCAAGTTTTGCAA shr
ZE172 5’-CCCCGGTACCTTAGGCTACCTTGGTGAATTGAGCTATTC shr
ZE173 5’-TTTTGGTACCTGATGTTAGAGGCTCTAGCGCT shr
ZE215 5’-TTTTTTATCGATGATCTAGATCCGACTCAAGCAAGTAAG shr
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Table 2: Plasmids used in this study 
Name Description Cloning method Reference 
pASK-
IBA-12 
Step-Tag expression vector  IBA 
pEB2 Strep-tag Shr A PCR fragment was amplified from GAS 
chromosome with Y-His-fwd/Strep-shr-rev 
primer set, cut with EcoRI & XhoI and ligated 
into pZSK-IBA-12 
This study 
pEB10 Strep-tag NTD A PCR fragment was amplified from pEB2 
using ZE58/ZE59 primers cut with XhoI and 
self-ligated 
This study 
pEB11  Strep-tag NTD-N1 A PCR fragment was amplified from pEB2 
using ZE58/ZE60 primers cut with XhoI and 
self-ligated 
This study 
pHSL2  Strep-tag NEAT2 A PCR fragment was amplified from GAS 
chromosome using ZE139/ZE140 primer set, 
cut with KpnI and ligated into pZSK-IBA-12 
This study 
pCB1 Express His-tag Shr  [45] 
pJRS700 Tm sensitive shuttle vector   [46] 
pXL2 Carries the shr ΔNEAT1 
allele 
A PCR fragment was amplified from pEB8 
using ZE168/ZE169 primer set, cut with ClaI 
and ligated into pJRS700. 
This study 
pXL3 Carries the shr ΔNEAT1-2 
allele 
A PCR fragment was amplified from pXL2 
using ZE171/ZE172 primer set, cut with KpnI 
and self-ligated 
This study 
pXL5 Carries the shr wt gene APCR fragment was amplified from GAS 
chromosome with ZE160/ZE170 primer set, cut 
with ClaI and ligated into pJRS700 
This study 
pXL13 Carries the shr ΔNEAT2 
allele 
A PCR fragment was amplified from pXL5 
using ZE171/ZE172 primer set, cut with KpnI 
and self-ligated 
This study 
pXL18 Carries shr fragment with 
upstream region 
A PCR fragment was amplified from GAS 
chromosome with ZE215/ZE170 primer set, cut 
with ClaI and ligated into pJRS700 
This study 
pXL14 Tm sensitive plasmid 
expressing the wt shr gene 
  [48] 
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CHAPTER II 
 
MECHANISMS OF INTRA- AND INTER-MOLECULAR HEME TRANSFER BY THE 
SHR PROTEIN OF GROUP A STREPTOCOCCUS 
 
Introduction 2 
 
Hemoglobin (Hb) and other hemoproteins that are released from lysing host cells are 
major iron sources for pathogenic bacteria. Upon erythrocyte lysis, the serum carrier haptoglobin 
forms a complex with Hb. Free in the blood, Hb spontaneously oxidizes to methemoglobin 
(metHb) and free heme is sequestered by the plasma hemopexin. To take advantage of these 
molecules, pathogens compete for the heme and transfer it across the cell envelope into the 
cytoplasm, where the iron is removed or the heme is incorporated in the bacterial machinery 
[98,144,145]. An emerging theme for heme transport in Gram-positive organisms is the use of a 
protein relay apparatus, in which heme is obtained from host molecules and delivered in a 
cascade fashion from the bacterial surface through the peptidoglycan layers to a cognate ABC 
transporter. The latter then mobilizes the heme across the cytoplasmic membrane [37,38]. A 
protein domain named NEAT (for NEAr-iron Transporter) often facilitates the capture and 
transfer of heme by the surface receptors [37-39]. NEAT domains are found in one or more 
copies in the heme-binding proteins of the different members of the Isd (Iron-regulated surface 
determinant) family. These receptors are well described in Staphylococcus aureus, Bacillus 
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species and Listeria monocytogenes [37-39]. Alternative heme relay apparatuses that use non-
NEAT heme-binding modules were recently identified in Corynebacterium diphtheriae and 
Mycobacterium tuberculosis [42,43]. 
Heme sequestering from host proteins in S. aureus is achieved by the cell-wall proteins 
IsdB and IsdH, which transfer the heme to a third receptor in the peptidoglycan, IsdA 
[107,116,117]. Heme is then passed to IsdC and then to the IsdEF proteins for import across the 
cell membrane [117,146]. B. cereus relies on a surface NEAT-containing receptor (IlsA) that 
interacts with uncharacterized partner proteins to import heme into the cell [123]. An Isd-like 
system involving the secreted NEAT-containing hemophores, IsdX1 and IsdX2, is used by 
Bacillus anthracis [40,147]. Similarly to S. aureus, heme obtained by IsdX1 and IsdX2 is 
transferred to IsdC, which conveys the ligand to the cytosol through the IsdEF transporter. In 
addition to IsdC, IsdX1 also transfers its heme to IsdX2.   
Multiple NEAT domains may be found in a single receptor, in which case they are 
numbered from the N-terminus of the protein. Isolated NEAT domains from various NEAT-
containing proteins exhibit major functional differences and contribute differently to the heme 
acquisition process. Many NEAT domains bind heme and/or hemoproteins [41,51,111-
119,148,149], whereas some also bind other ligands, such as extracellular matrix (ECM) 
components [104,148]. This functional diversity is often illustrated within a single protein 
harboring several NEAT domains. For example, both IsdX2 NEAT1 and NEAT5 from B. 
anthracis can scavenge heme from Hb, but only IsdX2 NEAT1 can transfer its heme to IsdC 
[147]. IsdX2 NEAT3 and NEAT4 can bind free heme and transfer it to IsdC, but are unable to 
obtain heme from Hb. In contrast, IsdX2 NEAT2 does not bind heme, but interacts with Hb. 
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In Group A Streptococcus (GAS), the conserved ten-gene operon sia (streptococcal iron 
acquisition system) participates in heme uptake [45]. The first gene in the sia locus, shr, 
expresses a composite surface receptor. Shr contains two NEAT domains separated by a series of 
leucine-rich repeats, a unique N-terminus region (NTD) with two copies of the uncharacterized 
module DUF1533 and a calcium binding EF hand [148,150]. Unlike other NEAT-containing 
hemoproteins receptors, Shr (and BslK from B. anthracis) are not attached to the peptidoglycan. 
Shr, which protrudes through the cell wall, is anchored to the cytoplasmic membrane by an 
hydrophobic segment at its C-terminus [48], whereas BslK associates with the S-layer on the 
bacterial surface [151]. Ligands recognized by Shr include heme, metHb, Hb-haptoglobin 
complex and some ECM proteins [45,48]. A recent study demonstrated that Shr binds heme 
through both of its NEAT domains. A separate region in Shr N-terminus mediates stable metHb 
binding, but possible transient binding by other parts of the receptor are not ruled out [148]. 
NEAT2 interacts with fibronectin and laminin in addition to heme. The full-length Shr and a 
protein fragment containing NTD and NEAT1 acquire heme from metHb in vitro [54,148]. 
Heme from Shr is efficiently transferred to the NEAT-like module in Shp, which is encoded by 
the second gene in the sia operon. Heme is then transferred from Shp to the SiaABC (HtsABC) 
transporter [152].  
The sia operon is found in several pyogenic streptococci. For example, S. equi 
zooepidemicus and S. dysgalactiae code for Shr orthologues with identical domain architecture. 
The function of these Shr proteins in heme uptake is yet to be studied. A homologue of Shr 
(SeShr) is also found in the genome of Streptococcus equi subsp. Equi; however, a frame shift 
mutation in the Seshr gene results in a truncated protein that binds metHb and hemoglobin-
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haptoglobin, but not heme or fibronectin [138]. As in GAS, the Shp orthologue (SeShp) binds 
heme and transfers it to the SiaABC (SeHtsABC) transporter [138,153]. In summary, heme 
acquisition strategies in Streptococci share some similarity with Isd and Isd-like systems, though 
important differences are found between these systems. 
Here we conduct for the first time a comprehensive kinetic study to determine the role of 
GAS Shr domains in heme acquisition, and we suggest a model for inter- and intra-molecular 
heme flow in the streptococcal system. 
 
Results 2 
NEAT1 is more efficient in acquisition of heme from metHb than NEAT2 
We recently showed that NTD-N1, a recombinant fragment of Shr containing the 
domains that bind metHb and heme (NTD and NEAT1, respectively), acquires heme from 
metHb in vitro [148]. To test whether NTD is essential for heme acquisition by NEAT1, we 
cloned and purified a recombinant Shr fragment containing the NEAT1 domain alone fused to 
maltose binding protein (MBP) (fig. S7). The molar extinction coefficient of heme-bound 
NEAT1 (ε410 nm = 136, 670 M-1 cm-1) was determined at 410 nm using the hemochromogen 
method [154]. ApoNEAT1 was incubated for 5 min on ice with metHb at 2:1 apoNEAT1/metHb 
molar ratio. The two proteins were then separated by affinity chromatography, allowing a 
selective binding of the NEAT1 protein. Western blot analysis of the elution fraction confirmed 
it contains only the NEAT1 protein without metHb contamination (fig S8). The UV-visible 
absorbance spectrum of the eluted NEAT1 had the typical Soret peak at 410 nm, indicative of 
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NEAT1-bound heme with ferric iron [148] (fig. 10A). These changes in the NEAT1 spectrum 
suggest heme acquisition by the apoNEAT1 domain. Control heme reconstitution experiments 
were carried out using 5 µM NEAT1 as purified from E. coli (fig. S9A), 5 µM MBP (fig. S9B) 
or buffer only, incubated with heme in increasing concentration (fig. S9C). The initial Soret band 
of NEAT1 (indicative of initial heme bound to the protein) increased significantly with the 
addition of heme to the protein solution from an absorbance of 0.20 to 0.65 at 20 µM heme. In 
contrast, when heme was added to MBP, the small and broad band (absorbance ~0.02) that was 
visible at the Soret region slightly expanded with heme addition and reached a maximum 
absorbance of only 0.071. These observations established that it is the NEAT1 domain that is 
readily associating with heme in the MBP-N1 fragment, and that MBP does not contribute 
significantly to these interactions. Consistent with previous observations, ELISA with 
immobilized NTD, MBP-N1, MBP and BSA showed the formation of a stable complex between 
metHb and NTD, and ruled out similar interactions between metHb and MBP (fig. S10). 
The ability of isolated NEAT2 domain to obtain heme from metHb was tested using the 
same methods. The molar extinction coefficient of heme-bound NEAT2 (ε410 nm =146, 000 M-1 
cm-1) was determined at 410 nm. Western blot analysis of the eluted protein showed no metHb 
contamination (fig. S8). The UV-visible absorbance spectrum of NEAT2 after metHb incubation 
showed a major peak at 426 nm and peaks at 410, 530 and 560 nm, indicative of bound ferrous 
and ferric heme (fig. 10B) [54,148]. Therefore, as we previously found for the acquisition of free 
heme from solution by Shr [148], NEAT2 reduced some of the ferric heme it acquired from 
metHb. The combined ratio Abs426nm/Abs280nm (0.51) and Abs410nm/Abs280nm (0.32) of apoNEAT2 
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treated with metHb is lower than the ratio Abs410 nm/Abs280nm (2.25) of apoNEAT1 upon metHb 
treatment. This suggests that apoNEAT1 acquired more heme from metHb than apoNEAT2.   
 
The N-terminal domain of Shr facilitates heme transfer from metHb to Shr 
To further investigate the transfer of heme from metHb to the different domains of Shr, 
rapid reaction studies were carried out on a stopped-flow spectrophotometer. The Shr domains in 
PBS were mixed individually at 25 ºC with different concentrations of metHb in PBS. Time-
resolved absorbance data were collected over the entire 340-700 nm wavelength span of the 
diode-array detector. Alternatively, time-courses of the reaction were collected at the wavelength 
of maximal change with a monochromator and a photomultiplier detector. The time-courses of 
the reactions of NTD-N1, NEAT1, NEAT2 and MBP versus metHb are shown in fig. S11. Over 
time, significant changes in absorbance at 414 nm were seen only with the NTD-N1 fragment. 
Therefore, in the stopped-flow experiments, NTD-N1 was the only tested fragment that 
efficiently acquired heme from metHb.  
Based on the observation described above, a detailed analysis of the heme transfer from 
metHb to NTD-N1 was carried out. The different spectra of NTD-N1 and metHb in the apo and 
holo forms are shown in fig. S12. ApoNTD-N1 at 2.5 µM final concentration was mixed with 
different amounts of metHb in a stopped-flow spectrophotometer equipped with a 
monochromator. The absorbance variations at 414 nm plotted as a function of time best fitted a 
triple exponential process at all the concentrations of metHb tested (fig. 11A). The observed rate 
constants for the fast phase (kobs1) at each concentration of metHb decreased hyperbolically with 
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increasing metHb concentration (fig. 11B). Both kobs2 and kobs3 did not show any linear or 
hyperbolic dependence on metHb concentration, and had average values of 0.034 s-1 and 0.003 s-
1, respectively (fig. 11C). These three kinetically distinct phases are consistent with the minimal 
kinetic model that we propose in Scheme 1. In brief, NTD-N1 devoid of heme exists in solution 
in two populations that are in slow equilibrium, with only one population proving able to form a 
complex with metHb. Slow equilibrium is defined here as being governed by rate constants for 
the interconversion of the two populations (i.e., k1 and k2 in Scheme 1) being slower than the rate 
of association of metHb with apoNTD-N1. After rapid association of metHb with apoNTD-N1 to 
yield a binary protein complex, the heme is transferred from metHb to apoNTD-N1, possibly 
followed by the slow release of heme in solution or by the slow dissociation of the binary 
complex to yield holoNTD-N1 and unloaded metHb. The presence of two populations of 
apoNTD-N1 in slow equilibrium is reminiscent of a proposed kinetic model previously proposed 
by Zou et al. to explain similar inverse concentration dependence kinetics for calcium (Ca2+) 
binding by the Ca2+ sensor, Ca-G1 [155]. Such type of kinetics has been recently reviewed by 
Vogt et al. [156]. The three well-separated phases observed in the stopped-flow 
spectrophotometer provide unequivocal evidence for the presence of multiple, temporally 
distinct kinetic steps. The presence of two populations in slow equilibrium and the rapid 
formation of the initial protein complex are supported by the inverse concentration dependence 
of kobs1, with fitting of the data to the equation: kobs1 = k1 + k2 *(Keq / (Keq + [metHb])) with R2 = 
0.99, establishing the values for k1 (0.1 s-1), k2 (1.7 s-1) and Keq (32 µM). Conformational changes 
or interactions with partner proteins have been shown to alter the spectral properties of protein-
bound heme in several hemoprotein [157-162]. 
51 
 
 
 
The first phase of the minimal kinetic model proposed in Scheme 1 suggests that the 
observed changes in the Soret region reflect the formation of a complex between metHb and 
NTD-N1. To test whether complex formation (in the absence of heme transfer) could result in 
spectral perturbations, the UV-visible absorbance spectrum of metHb (3 µM in PBS) was 
compared to that of metHb in a mixture with NTD (3 and 4.5 µM respectively, in PBS). Unlike 
NTD-N1, the NTD fragment can only bind to MetHb, but not heme [148]. The Soret peak of 
metHb slightly decreased and shifted from 406 nm toward 408 nm in presence of NTD (fig. 
S13A). The UV-visible absorbance spectrum of NTD in PBS is shown in fig. S13B. Then again, 
the addition of 4.5 µM of MBP (which does not interact with metHb) to 3 µM metHb in PBS did 
not lead to any change in the UV-visible absorbance spectrum of metHb (fig. S13A). It is 
conceivable that like with NTD, the association of NTD-N1 with metHb leads to spectral 
changes in the Soret region as proposed in Scheme 1.  
The transfer of heme from metHb to NTD-N1 within the binary protein complex is 
assigned to the second phase (kobs2) observed in the stopped-flow spectrophotometer, which is 
defined by an average first-order rate constant of 0.034 s-1. The slowest phase (kobs3) observed in 
the stopped-flow spectrophotometer had an average first-order rate constant of 0.003 s-1. The 
value of kobs3 is not significantly different from the literature values for the dissociation of ferric 
heme from the β subunits of human metHb (~0.002 s-1) [163]. Therefore, we suggest the third 
phase corresponds to the dissociation of heme from metHb in solution that occurs after the heme 
transfer within the binary protein complex. Alternatively, the third phase may represent the slow 
dissociation of the holoNTD-N1-apometHb complex. 
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One possibility for the two populations inferred in resting NTD-N1 by the kinetic 
analysis is because of different oligomerization states of the protein. Analytical gel filtration was 
performed to evaluate the oligomerization state of NTD-N1 in solution. The molecular weight 
(MW) of NTD-N1 was determined by comparing its elution volume with those of known protein 
standards (aldolase, catalase and bovine serum albumin) on a Superose-6 10/300 column (GE 
Healthcare) in PBS. Most of the NTD-N1 protein in these experiments was excluded from the 
column with an elution volume (15.7 ml, fig. S14A) that was similar to that of aldolase (MW of 
160 kDa, elution volume 15.4 ml, fig. S14B), thereby establishing a MW of ~140 kDa for NTD-
N1, consistent with the presence of NTD-N1 dimers (~142 kDa). 
 
Heme transfer from metHb to the full-length Shr  
The kinetics of heme acquisition from metHb by the full-length Shr was carried out and 
compared to the heme transfer between metHb and the NTD-N1 fragment. Stopped-flow 
experiments were conducted by mixing various concentrations of metHb in PBS with 2.5 µM 
apoShr in PBS. The changes in the absorbance at 414 nm recorded over time indicated a triple 
exponential process (fig. 12A). The observed rate constants of the first and second phases (kobs1 
and kobs2) increased hyperbolically with increasing metHb concentration (fig. 12B & 12C). The 
limiting rate constants were determined as the asymptotic estimates at high metHb 
concentrations, with values of 6.5 ± 0.7 s-1 (R2 = 0.99) for the fast phase, which defines an 
intercept of 1 s-1 on the y axis, and 2.3 ± 0.6 s-1 (R2 = 0.99) for the second phase. The observed 
rate constants of the third phase (kobs3) did not show an unequivocal dependence on metHb 
concentration with kobs values that could be fit either with a hyperbolic saturation dependence or 
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a linear dependence (fig. S15). Each fit returned a rate constant value for kobs3 at infinite 
concentration of metHb of ~0.15 ± 0.07 s-1. 
 
NEAT1 mediates rapid heme transfer to Shp 
Heme transfer from Shr to Shp has been previously reported [54]. However, the role of 
Shr NEAT domains in the process was not studied. To determine whether the two NEAT 
domains of Shr constitute heme sources for Shp, stopped-flow experiments were carried out. Shp 
was cloned and the recombinant protein was purified by affinity chromatography (fig. S7). The 
molar extinction coefficient at 410 nm (ε410 nm =116, 000 M-1 cm-1) and the UV-visible 
absorbance spectrum of the heme-bound recombinant Shp were determined (fig. S16). ApoShp 
at a final concentration of 2.5 μM was mixed in a stopped-flow spectrophotometer with various 
concentrations of holo NEAT1 or NEAT2, and the spectral changes were monitored over the 
entire 340-700 nm wavelength range of the diode-array detector. The time course of the reactions 
for holoNEAT1 versus apoShp best fitted a double exponential process (fig. 13A), with both 
observed first-order rate constants being linearly dependent on the concentrations of 
holoNEAT1. The second-order rate constants estimated from the slopes of the plots in fig. 13B 
and 13C were 2.50 ± 0.04 s-1 μM-1 (R2 = 0.99) for the fast phase (fig. 13B) and 0.017 ± 0.004 s-1 
μM-1 (R2 = 0.89) for the slow phase (fig. 13C).  
The time course of the reactions for holoNEAT2 versus apoShp also best fitted a double 
exponential process (fig. 13D). The observed rate constants for the fast phase showed a 
saturation behavior dependent on the concentration of holoNEAT2, with a rate limiting value at 
54 
 
 
 
saturating NEAT2 of 0.010 ± 0.001 s-1 (fig. 13E). The apparent first-order rate constants for the 
slow phase were nearly independent of the concentrations of holoNEAT2, with an average 
observed rate constant of (2.1 ± 0.5) x 10-5 s-1.   
 
Heme exchange between Shr NEAT domains 
We sought to determine whether NEAT2 could acquire heme from NEAT1. ApoNEAT2 
was mixed with holoNEAT1 at 2:1 apoNEAT2/NEAT1 molar ratio for 5 min. NEAT2 was then 
separated from NEAT1 by affinity chromatography, allowing a selective binding of the NEAT2 
fragment. Eluted NEAT2 was analyzed by SDS-PAGE and showed no NEAT1 contamination 
(fig. S17). The UV-visible spectrum of NEAT2 after incubation with NEAT1 revealed two major 
peaks at 410 nm and 426 nm, corresponding to bound ferric and ferrous heme, respectively (fig. 
14A). Time course of the heme transfer from NEAT1 to NEAT2 was monitored in a stopped-
flow spectrophotometer equipped with a monochromator, mixing apoNEAT2 (2.5 μM final 
concentration) with different concentrations of holoNEAT1. The time course of the heme 
transfer was biphasic and best fitted a double exponential process. The fast phase was linearly 
dependent on the concentration of holoNEAT1. A second-order rate constant of 0.15 ± 0.02 s-1 
μM-1 (R2 = 0.94) was obtained from the slope of kobs1 vs holoNEAT1 concentrations (fig. 14B). 
The slow phase exhibited no significant dependence on NEAT1 concentration and had an 
average observed rate constant of 0.06 ± 0.01 s-1. In a similar experiment using holoNTD-N1 as 
heme donor to apoNEAT2, the reaction best fitted a single exponential. The observed rate 
constants were linearly dependent on holoNTD-N1 concentration. The second order rate constant 
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for heme acquisition was determined as above and resulted in a value of 0.66 ± 0.05 s-1 μM-1 (R2 
= 0.99). Therefore, Shr NTD contributes only slightly to the transfer of heme from NEAT1 to 
NEAT2. To test whether NEAT2 can readily transfer its heme back to NEAT1, time course of 
the reaction of heme transfer from holoNEAT2 (35 μM) to apoNEAT1 (2.5 μM) was carried out. 
The spectral changes were monitored at 427 nm. The reaction best fitted a double exponential 
process, with an observed rate constant at saturating concentration of 1.1 ± 0.2 s-1 for the fast 
phase. The observed rate constant of the second phase was negligible (0.003 ± 0.003 s-1). 
 
Discussion 2 
Heme flow between proteins and/or isolated NEAT domains was studied in various Isd-
proteins from S. aureus and B. anthracis. Despite the overall similarity in the organization of the 
heme relay systems and protein homologies, the transfer process appears to be different in 
different proteins. In several cases, heme shuttle is mediated by an active process involving 
protein-protein interactions, as is found in the transfer from IsdA to IsdC [146] and from IsdB to 
IsdA [149] in Staphylococcus and the transfer between bacilli proteins IsdX1 to IsdC [40]. In 
other examples, including the acquisition of heme by IsdH from Hb in S. aureus [116] and the 
transfer of heme from IsdX2 to IsdC of B. anthracis [147], heme transport is suggested to be 
passive, mediated by heme dissociation and capture from solution. The Sia heme relay system in 
GAS is different from those characterized in Bacillus and Staphylococcus by the number and the 
nature of the interacting proteins. In addition, the mechanism of heme transport was investigated 
in detail only for the relay between Shp and SiaA, the binding protein of the SiaABC 
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transporters. Here we carried out analyses of the functional domains in Shr, the first receptor in 
the relay, and assessed the domains’ role in heme acquisition and delivery to Shp. 
We previously established that both NEAT1 and NEAT2 could capture free heme from 
solution [148]. In this study, we found that the measured values of the Soret/280 nm ratio after 
incubation of apoNEAT2 and apoNEAT1 with metHb and separation by affinity 
chromatography were ~0.83 and ~2.25, respectively. This absorbance ratio is commonly used as 
an estimation of heme content [147,164,165] and suggests that the process of heme uptake from 
metHb is more effective with NEAT1 than it is with NEAT2 (fig. 10A & fig.10B). However, in 
the stopped-flow experiments conducted with isolated Shr fragments, only the NTD-N1 fragment 
could efficiently acquire heme from metHb, while NEAT1 and NEAT2 did not (similar 
observations were made with independent protein preparations). There is no obvious basis for the 
difference in the capacity to obtain heme from metHb observed with isolated NEAT domains in 
the static heme transfer, versus the rapid reaction experiments. It seems possible, however, that 
the higher concentration of NEAT-proteins needed for the heme transfer experiments carried out 
on a column, in comparison to that needed for the stopped-flow (40 μM and 2.5 μM, 
respectively), may favor a protein state, much like a certain fold or oligomerization status that is 
prone for heme uptake. Enzyme concentration was shown to affect reaction kinetics in some 
cases [166]. The inclusion of the metHb-binding region, NTD, in the NTD-N1 fragment may 
have increased heme capture by NEAT1 by possibly fostering stable interactions with metHb, or 
shifting the protein population balance towards the state that favors heme uptake. The suggestion 
of two protein populations, only one of which participates in heme uptake, is also consistent with 
the kinetics of heme uptake by NTD-N1 as discussed below.  
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Heme transfer from metHb to IsdH NEAT3 is ~2-fold faster in the presence of the 
metHb-binding domain, IsdH NEAT1 [116]. Nevertheless, substantial differences exist between 
the heme transfer events mediated by Shr NTD-N1 and IsdH. On the one hand, heme transfer 
from metHb to IsdH NEAT3 in presence of IsdH NEAT1 is a slow biphasic process with rate 
constants similar to the rate constant of free dissociation of heme from metHb [116]. Conversely, 
Shr NTD-N1 fragment obtained heme from metHb faster and in a unique three-phase process 
that was not seen in other characterized heme relays: a rapid first phase with apparent rate 
constants that decreased hyperbolically with the increase in metHb concentrations (fig. 11B), 
followed by the second and third phases that did not show linear or hyperbolic dependence on 
metHb concentrations. While the average rate constant of the third phase does not deviate 
significantly from that of free dissociation of heme from the β-subunit of metHb (~0.002 s-1) 
[163], the rate constant of the second phase is ~20-fold higher. The inverse correlation between 
the apparent rate constants and metHb concentrations observed during the first phase is 
consistent with the minimal kinetic model proposed in Scheme 1, and is explained by a slow 
interconversion between two forms of apoNTD-N1 that are present in solution, with only one 
form that binds metHb in a productive fashion that results in the subsequent heme transfer. The 
increasing amount of metHb added to the mixture progressively altered the equilibrium, due to 
the formation of a complex between metHb and the binding form of apoNTD-N1. Formation of 
different multimeric states is one of the possible explanations for the coexistence of different 
forms of apoNTD-N1. Dimers formation by NTD-N1 was supported by the analytical gel 
filtration experiments, and ELISA confirmed that stable interactions between NTD and metHb 
are formed (fig. S10, S14 and [148]). The first step of Scheme 1 implies that complex formation 
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without heme transfer results in the spectral changes. This hypothesis was supported by the 
changes observed in the UV-visible absorbance spectrum of metHb when it was incubated with 
NTD, but not with MBP. During the second phase, the intermediate complex apoNTD-N1-
metHb may facilitate the transfer of heme from the metHb directly to NEAT1 (Scheme 1). The 
third phase may represent the release of heme in solution from the β-subunit of metHb, as 
suggested by the low observed rate constants. Alternatively, it may represent the slow 
dissociation of the holoNTD-N1-apometHb complex. 
Like the isolated NTD-N1, the full-length protein acquired heme from metHb in a time 
course that best fitted a triple exponential equation at all tested metHb concentrations. However, 
the observed rate constants for the first and second phases were hyperbolically dependent on 
metHb concentration, whereas the observed rate constants of the third phase did not show an 
unequivocal dependence on metHb concentration (fig. 12B & C and fig. S15). The fit of kobs1 
values defines a y intercept of 1 s-1, which corresponds to the reverse of the heme transfer to 
NEAT1 domain. The first and second phases were ~190 and ~65 times faster, respectively, than 
the second phase of heme transfer from metHb to apoNTD-N1. We propose that these two 
phases correspond to the direct heme transfer from metHb to NEAT1 and to NEAT2, 
respectively (Scheme 2), with the first process ~3 times faster than the second (6.5 ± 0.7 s-1 
versus 2.3 ± 0.6 s-1). The third phase may correspond to the dissociation of the Shr-metHb 
complex (Scheme 2). Protein-protein interactions involving hemoproteins and cognate partners 
can result in changes of the absorbance properties of the bound heme ([157-162] and fig S13A). 
In summary, although both the NTD-N1 fragment and the full-length Shr acquired heme from 
metHb in a three-phase process, significant differences are found between the mechanisms 
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involved. The full-length protein, which contains two heme-binding domains, scavenged heme 
from metHb several fold faster than NTD-N1.   
Shp, the adjacent protein to Shr in the Sia system, does not efficiently acquire heme from 
metHb, but readily scavenges it from Shr [54]. The stopped-flow kinetics experiments in this 
study revealed that holoNEAT1 transfers heme to apoShp in a two-phase process with second 
order rate constants of 2.5 ± 0.04 s-1 μM-1 and 0.017 ± 0.004 s-1 μM-1, and with both phases 
linearly dependent on holoNEAT1 concentrations (fig. 13B and C). This observation is 
indicative of two heme transfer events occurring simultaneously from two species of 
holoNEAT1 to apoShp, with one species transferring its heme ~150 times faster than the other 
species (Scheme 3).  Different multimeric states, other protein rearrangements or the presence of 
a certain fraction of protein not fully competent for heme uptake, may be invoked to explain the 
presence of two phases here. Similarly, two phases were observed in the transfer reactions 
between holoNEAT2 and apoShp. The fast phase was dependent on the concentration of 
holoNEAT2 in a saturable manner, and the slow phase was independent of holoNEAT2 
concentrations. The observed limiting value at holoNEAT2 saturation of the fast phase (0.01 ± 
0.001 s-1) is comparable to the observed rate constant of the slow phase in the transfer reactions 
between holoNEAT1 and apoShp. In conclusion, NEAT1 appears to donate heme directly to Shp 
probably by an active process, whereas heme transfer from NEAT2 to Shp is a slow process that 
likely relies on the free dissociation of heme in solution. Finally, since the rate constant of the 
slow phase observed in the transfer reaction between holoNEAT2 and apoShp was nearly equal 
to zero, it may be an artifact due to damaged or not fully functional protein.    
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Here we explored the heme flow within Shr using both qualitative and quantitative 
assays. ApoNEAT2 efficiently acquired heme when mixed in excess with holoNEAT1. The 
kinetics of heme transfer from holoNEAT1 to apoNEAT2 showed that this reaction was ~17 
times slower than the reaction of heme transfer from holoNEAT1 to apoShp, indicating that 
NEAT1 preferentially transfers its heme to Shp rather than to NEAT2. The reverse heme transfer 
reaction from holoNEAT2 to apoNEAT1 suggested that NEAT2 transfers heme to NEAT1 faster 
than it receives heme from NEAT1. This implies that the transfer of heme from NEAT1 to 
NEAT2 only occurs as an alternative, probably in situations where heme is present in excess. 
The observed differences in the ability of Shr NEAT domains to obtain and transfer heme 
illustrate an example of functional diversity of these protein modules when present in multiple 
copies within a single protein. Another example of NEAT functional diversity is evidenced by 
the five NEATs of IsdX2 hemophore in B. anthracis [147]. 
 Taken together, our results shed light on the intra- and inter-molecular mechanisms of 
heme acquisition and transfer by Shr. We propose that Shr binds metHb through NTD and forms 
an intermediate protein complex, which may facilitate direct heme transfer from metHb to 
NEAT1 and NEAT2, and eventually the release of heme from metHb in solution. Heme 
scavenged by NEAT1 is rapidly transferred to Shp for delivery into the cell by the SiaABC 
transporter.  Heme acquired by NEAT2 is stored and transferred back to NEAT1 when needed, 
possibly when heme availability is limiting (fig. 15). The hemolytic GAS can colonize a variety 
of sites in the human body, including the mucosal membranes in the upper respiratory tract and 
the skin. This pathogen could also spread via blood and various tissues producing bacteremia, 
massive necrosis, or both. Therefore, during infection, GAS is confronted with a changing 
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environment where iron and heme could be highly restricted or toxic in excess. The possible 
function of Shr as a modulator of heme uptake, as raised by this investigation, could be very 
important for GAS adaptation during the infection process.   
While this manuscript was in preparation, a study [167] was published suggesting that 
apoShr obtains heme from metHb in a biphasic process with reaction rate constants of 0.027 s-1 
and 0.0042 s-1. Those measurements were carried out at a single metHb concentration without 
evaluation of their dependence on metHb concentration [167]. In the present study, we tested 
heme transfer from metHb to apoNTD-N1 and to apoShr across multiple concentrations of 
metHb. This comprehensive analysis allows us to establish that heme uptake from metHb 
involves a three-phase process with reaction rate constanzts of 6.5 s-1, 2.3 s-1 and 0.15 s-1 under 
saturating conditions. For the transfer to Shp, we found in this study that while isolated NEAT1 
readily gives its heme to Shp, NEAT2 does not. This inefficient transfer of heme from NEAT2 to 
Shp might explain the partial heme transfer with the full-length Shr (37% of the heme is not 
transferred) recently reported by Lu et al [167]. 
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Materials and methods 2 
The bacterial strains, media and antibiotics 
Escherichia coli (E. coli) cells were grown aerobically in Luria–Bertani (LB) medium at 37 °C 
supplemented with 100 µg/ml of ampicillin. The E. coli strains used in this study are listed in 
Table 3. 
 
Recombinant Shr and Shp proteins 
The plasmids and primers used in this study are listed in Tables 3 and 4. The cloning of the 
recombinant Shr proteins, NTD-N1 (pEB11) and NEAT2 (pHSL2), each expressed as N-
terminal fusion to the Strep-Xpress® epitope was previously described [148]. Shr NEAT1 
fragment is insoluble when expressed as an isolated domain [148]. MBP was previously shown 
to help in the solubility of recombinant proteins; therefore, an N-terminal fusion of Shr NEAT1 
to His-MBP was constructed. Cloning was performed using the Gateway® technology 
(Invitrogen) according to the manufacture protocol. In brief, NEAT1 region was amplified from 
NZ131 chromosome with ZE353/354 primer set and was cloned into the entry vector 
pDONRTM221 by BP ClonaseTM II. The resulting entry clone, pYSH5, which carries NEAT1 
fragment flanked by the attL sites, was then allowed to interact with the destination vector 
pDEST-His tag-MBP. The produced plasmid, pYSH6, expresses a His-tag-MBP-NEAT1 fusion 
protein from the TAC promoter. The construction of Shp-His expression vector was 
accomplished by TOPO® directional cloning according to the manufacturer instruction 
(Invitrogen, K101-01). The shp ORF was amplified from NZ131 chromosome using the 
63 
 
 
 
ZE406/ZE407 primer set and introduced into the pET101/D-TOPO vector. The resulting plasmid 
pOM101 codes for a Shp-His tag fusion protein expressed from the T7 RNA polymerase 
promoter.  
 
Proteins expression and purification 
NTD-N1 and NEAT2 were prepared as previously described [148]. Expression of His-tagged 
MBP-NEAT1 and His-tagged Shp was induced overnight at 27 °C with 1mM isopropyl β-D-1-
thiogalactopyranoside. Cells were harvested and resuspended in an extraction buffer (20 mM 
Tris pH 8, 100 mM NaCl, 0.1% Triton X-100) with the addition of 0.5 mg/ml and Complete, 
mini-EDTA-free protease inhibitor cocktail tablets (Roche), then lysed by sonication. The cells’ 
pellet was centrifuged and the cleared lysate was then applied to a 5 ml HisTrap HP affinity 
column (nickel column) and purified using a FPLC. Purified proteins were dialyzed in PBS 
buffer (10 mM phosphate-buffered saline, 100 mM NaCl, pH 7.4) prior to their use for 
experiments. Western blot analysis of recombinant Shp was carried out using anti-His antibodies 
from mouse (Sigma). 
 
Preparation of apoproteins, measurement of heme and protein concentrations 
Preparation of apoproteins and total protein measurements were performed as previously 
described [148]. Heme concentration was determined by the absorbance at 410 nm using Beer’s 
law (A= εbc, where ε is the molar extinction coefficient at 410 nm of the corresponding heme-
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bound protein, b is the path length of the sample and c is the concentration of heme in the 
sample). 
 
Heme transfer experiments 
ApoNEAT1 and apoNEAT2 (200 nmoles of each protein in 2 ml of PBS) were mixed with 
metHb (100 nmoles in 3 ml of PBS). The final concentrations of apoNEAT proteins and metHb 
in the 5 ml mixtures were 40 and 20 µM, respectively. After 5 min, the mixtures were then 
loaded on a HisTrap HP affinity column or Strep-Tactin Superflow column, respectively, to 
separate the Shr fragments from metHb. Trace metHb was removed by washing several times 
(10 column volumes) with His-tag wash buffer (20 mM sodium phosphate pH 7.4, 500 mM 
NaCl, 30 mM imidazole) or Strep-tag wash buffer (100 mM Tris-HCl pH 8.0, 250 mM NaCl, 1 
mM EDTA). Subsequently, the immobilized proteins were eluted with His-tag elution buffer (20 
mM sodium phosphate pH 7.4, 500 mM NaCl, 500 mM imidazole) or Strep-tag elution buffer 
(100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin). Spectroscopic 
analysis (250-700 nm) of the apoproteins before and after treatment with metHb was carried out 
using a Varian Cary 50 Bio spectrophotometer. All UV-visible spectra were subtracted from 
their corresponding background absorbance at 700 nm.  The same procedure was used for heme 
transfer from NEAT1 to NEAT2, with the exception that apoNEAT2 (200 nmoles in 2 ml of 
PBS) was mixed with holoNEAT1 (100 nmoles) for 5 min and the two proteins were separated 
using a Strep-Tactin Superflow column. 
 
Heme reconstitution, Enzyme-Linked ImmunoSorbent Assays (ELISA) 
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The heme reconstitution and ELISA experiments were conducted as described in [148]. 
 
Stopped-flow analysis 
Rapid kinetics was carried out on a Hi-Tech SF-16 stopped-flow spectrophotometer. The 
reacting apoproteins were mixed individually in PBS at 25 ºC with different concentrations of 
the corresponding holoprotein. All concentrations of heme-loaded proteins were based on the 
absorbance of heme bound to the protein. All concentrations used maintained pseudo-first order 
conditions. Absorbance data were collected over the entire 340-700 nm wavelength span of the 
diode-array detector. Alternatively, time-courses of the reaction were collected at the wavelength 
of maximal change with a monochromator. The optical path length for all the stopped-flow 
experiments was set to 2 mm. 
 
Data analysis 
The absorbance traces at individual wavelength were analyzed using KinetAsyst 3 software (Hi-
Tech Scientific) and KaleidaGraph (Synergy Software). Transients were fitted using the standard 
double or triple exponential expression (eq. 1, 2) 
A = C1e-kobs1t + C2e-kobs2t +b        Eq. 1 
A = C1e-kobs1t + C2e-kobs2t +C3e-kobs3t+b       Eq. 2 
Where A is the absorbance at selected wavelength, kobs1, kobs2 and kobs3 are the observed rate 
constants for the different phases, respectively; C1, C2 and C3 are the relative amplitude values 
for the different phases; and b is an offset value to account for a non-zero baseline. 
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Table 3: Strains and Plasmids used in this study 
Name Description Source/Reference 
Strains 
     E.coli  Top10 
    E.coli  BL21 Star 
   E.coli One shot Omni Max2-TI 
 
  
Host for pOM101 propagation 
Host for pOM101 expression  
Host for pYSH6 expression  
 
 
Invitrogen 
Invitrogen 
Invitrogen 
Plasmids 
pEB11 
 
pHSL2 
 
            pDONRTM221 
           pDEST-His tag-MBP 
           pYSH5 
           pYSH6 
           pET101/D-TOPO  
           pOM101 
 
 
Expresses Strep tag-NTD-N1 from Ptet 
 
Expresses Strep tag-NEAT2 from Ptet-  
 
Gateway® Donor vector with attP sites  
Gateway® Destination vector with attR sites 
attL-NEAT1-attL entry vector  
Expresses His tag-MBP-NEAT1 from Ptac  
Directional TOPO® TA cloning vector  
Expresses Shp-His tag from PT7 
 
[148]  
 
[148] 
 
Invitrogen 
[168] 
This study 
This study 
Invitrogen 
This study 
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Table 4: Primers used in this study 
 
Name Sequence Description 
ZE353 
 
GAGAACCTGTACTTCCAGTCTTATCAAGCAG
GTGAGGTTTCT 
 
Sense primer for Shr NEAT1 
domain 
 
ZE354 
 
GGGGACCACTTTGTACAAGAAAGCTGGGTA
TTAATCATCAGTTTCTACCTGATAACC 
 
Anti-sense primer for Shr 
NEAT1 domain 
 
ZE406 GATAAAGGTCAAATTTATGGATG Sense primer for shp  
 
ZE407 GTCTTTTTTAGACCGAAACTTATC Anti-sense primer for shp
ZE139 CCCCGAATTCTTAAATCAAAAACAATTGCGT
G 
Sense primer for  Shr NEAT2 
domain 
ZE140 AAAAGGTACCTTAGACAACCTTTGCCTTCTC
TG 
Anti-sense primer for Shr 
NEAT2 domain 
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CHAPTER III 
 
DISCOVERY OF HUPZ, THE FIRST STREPTOCOCCAL HEME OXYGENASE 
 
Introduction 3 
The restriction of free iron in the mammalian host constitutes a severe limitation to 
bacterial infections. Most of the biologically available iron in mammalians is bound to 
protoporphyrin IX in heme molecules, the vast majority of which are sequestered by proteins. 
Bacterial pathogens overcome this nutritional sequestration using elaborated systems that allow 
them to scavenge and transport heme from host hemoproteins into the bacterial cell 
[37,98,144,145]. A few mechanisms then allow bacteria to retrieve iron from the porphyrin 
center [56]. The most common one relies on oxidative degradation of the porphyrin ring by 
cytoplasmic enzymes known as heme oxygenases (HO) [57]. When supplied with electron 
donors, the canonical HOs break down heme to CO, α-biliverdin and free iron [60,169].  
The first bacterial HO discovered is HmuO, a homologue of the human HO-1 found in 
the pathogen Corynebacterium diphteriae [72,73]. Subsequently, several other HOs were 
identified and characterized in Neisseria meningitides (HemO) [74], Clostridium species 
(HemO) [75,76] and Pseudomonas aeruginosa (PigA or pa-HO and BphO) [77,78]. Like the 
mammalian HO-1, all of these HOs consist of monomeric α-helices with similar folds and 
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degrade heme to α-biliverdin [66], with the exception of PigA which produces an unusual 
mixture of  β- and δ-biliverdin [77].  
A group of bacterial HOs that are structurally different from the mammalian HO-1 is 
represented by IsdG and IsdI from Staphylococcus aureus. The structure of enzymes from the 
IsdG family consists of a homodimeric β-barrel with two separate active sites [82,83]. Unlike 
HmuO-type enzymes, IsdG catalyze the production of staphylobilin, an oxo-bilirubin 
chromophore and not biliverdin [81]. Members of the IsdG family include HmuD and HmuQ 
from Bradyrhizobium japonicum [84], MhuD from Mycobacterium tuberculosis [85] and the 
IsdG homologues from Bacillus anthracis [87] and Staphylococcus lugdunensis [86].  
A separate group of heme degrading enzymes whose products are not characterized was 
described in some pathogens including HemS from Yersinia enterocolitica [89], ChuS from 
Escherichia coli [88] and HemS homologue from Bartonella henselae [90]. Biochemical data 
supporting heme degradation in the presence of reducing agents was only shown for the last two 
examples [88,90]. The high sequence homology shared by these three proteins suggests their 
relatedness. The crystal structure of ChuS revealed a unique structure consisting of two central 
sets of antiparallel β-sheets, each flanked by two pairs of α-helices [88]. 
A new family of bacterial HOs with no homology to previously described enzymes was 
recently uncovered in Campylobacter jejuni (Cj1613c) [91], Helicobacter pylori (HugZ) [92] 
and Vibrio Cholerae (HutZ) [93]. Members of this family share weak sequence similarities with 
FMN-binding proteins and form dimers [93,94]. The crystal structure of HugZ was recently 
resolved; this protein adopts a split β-barrel fold that is characteristics of FMN-binding proteins, 
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however, actual FMN binding was not demonstrated. [94]. This structure is distinctive from that 
of HmuO-like or IsdG-like proteins. Interestingly, like PigA, HugZ has a unique δ-meso 
regiospecificity for cleaving the ring in the heme molecule [92], whereas HutZ is proposed to 
have both β- and δ-meso regioselectivity [93]. 
Heme uptake in Group A Streptococcus (GAS) is mediated by a conserved ten-gene 
operon, sia (streptococcal iron acquisition system) that is directly repressed by the iron-
dependent regulator MtsR [45,47]. Shr, the product of the first gene in the sia locus is a complex 
surface receptor. It contains two heme-binding NEAT domains separated by a series of leucin-
rich repeats, a calcium binding EF hand and a unique N-terminus region (NTD) which harbors 
two uncharacterized DUF1533 modules [148,150]. Shr is attached to the cytoplasmic membrane 
by a hydrophobic tail located at its C-terminus and is exposed at the bacterial surface by 
protruding through the peptidoglycan layer [48]. Different regions of the protein recognize and 
interact with various ligands including heme, methemoglobin (metHb), hemoglobin-haptoglobin 
complex and some ECM proteins [45,48,148].  The full-length Shr and a fragment of the protein 
that includes NTD and NEAT1 (NTD-N1) obtain heme from metHb in vitro [54,148]. Heme 
acquired by Shr is efficiently transferred to Shp, the protein encoded by the second gene in the 
sia operon, which in turn transfers it to the SiaABC (HtsABC) transporter [152]. Recent kinetic 
and spectroscopic analyses indicate that Shr and NTD-N1 fragment scavenge directly heme from 
metHb by two distinct and unprecedented three-phase processes. Additionally, NEAT1 
efficiently transfers its heme to Shp in a biphasic process, whereas NEAT2 does not and may 
serve as temporary heme storage on the bacterial surface. Furthermore, a reversible heme 
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exchange occurs between NEAT1 and NEAT2, constituting the first example of intra-molecular 
heme transfer between NEAT domains.    
 The fate of the imported heme inside the streptococcal cell remains unknown, as to date, 
a heme oxygenase has not been identified in Streptococci. Herein, we report the identification of 
the first heme oxygenase described in the Streptococcus genus. We provide biochemical 
evidences for heme binding and degradation by the enzyme and we show that it is the 
representative of a new family of heme oxygenases.   
 
Results 3 
Heme binding by HupZ 
GAS utilizes host heme containing proteins as iron source during infection [44]. This 
implies that the bacterium possesses mechanisms that allow it to retrieve iron from heme. This 
function is commonly carried out by HOs which catalyze the enzymatic cleavage of the 
porphyrin ring releasing free iron, CO and biliverdin [60]. Homologues of HOs are absent from 
the streptococcal genome, raising an intriguing mystery regarding heme utilization by GAS. 
Microarray analysis of MtsR-regulated genes identified putative gene (Spy49_0662) that was 
overexpressed in the mtsR mutant strain, suggesting its implication in iron or heme metabolism 
[170]. Spy49_0662 translates into a small protein of about 18.5 kDa with no secretion signal 
indicating that the protein likely functions in the cytoplasm. In silico analysis showed that this 
protein contains a module that belongs to the superfamily of the signature domain of the 
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pyridoxamine 5'-phosphate oxidase (PNPOx). The PNPOx domain is found in FMN binding 
enzymes.     
To test its role in iron utilization, we cloned and expressed Spy49_0662 from M49 GAS 
in E. coli as a C-terminal fusion to hexa-histidine tag. The recombinant protein was purified on 
an affinity column using FPLC. The cell lysate had a yellow color that was retained in the 
affinity column during purification. However, the yellow substance was separated from the 
protein and was eluted out of the column in different protein-free fraction. SDS-PAGE analysis 
confirmed the presence of a single protein band that migrated to the expected size of 18.5 kDa 
(fig. S18A). Subsequently, UV-visible spectroscopic analysis was conducted on the different 
fractions and revealed that the absorbance spectrum of the yellow fraction is consistent with that 
of oxidized FMN (fig. S18B). In contrast, the spectrum of the purified recombinant protein 
included bands at 334 and 405 nm (fig. S18C) which suggest that it is co-purified with reduced 
FMN [171]. Heme titration experiments were then carried out to test whether the Spy49-0662 
protein binds heme. Various concentrations of hemin chloride were added to 40 µM of the 
purified protein in 20 mM sodium phosphate buffer, pH 7.4. Upon hemin addition, a Soret peak 
appeared at 414 nm and increased with incremental addition of hemin. The peak at 414 nm 
progressively shifted toward 420 nm and this shift coincided with the appearance of two bands at 
530 and 560 nm, consistent with the characteristic spectrum of bound ferrous heme (fig. 16A). 
The plot of the differential absorbance at 414 nm as a function of hemin concentration indicated 
that the protein bound heme to saturation at 40 µM of hemin, suggesting a 1:1 binding ratio (fig. 
16B). On the other hand, the characteristic peaks of bound heme were absent when various 
concentrations of hemin were added to the buffer without the protein (fig 16C). Taken together, 
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these data established that Spy49-0662 expresses a new heme binding protein in GAS. The 
protein was therefore named HupZ (for heme utilization protein). The molar extinction 
coefficient for heme-bound HupZ was determined at 414 nm using the pyridine hemochromogen 
method and resulted in ε414 nm = 110000 M-1 cm-1 (fig. S19).  
 
Heme degradation by HupZ 
Heme degradation by HOs requires a source of reducing equivalent which is provided in 
mammals by the combined action of NADPH and cytochrome P450 reductase (CPR) [60,66]. 
While the native redox partner for the bacterial HOs is mostly unknown, CPR and ascorbic acid 
are typically used for in vitro heme degradation studies. HoloHupZ was prepared by mixing the 
apoprotein with hemin chloride at a concentration ratio of 1:1.5 (protein to hemin). After 30 min 
incubation on ice, the mixture was dialyzed then gel filtered to separate the holoprotein from 
excess free heme. Catalase at a final concentration of 2 µM was added to 20 µM holoHupZ in 20 
mM sodium phosphate buffer to prevent non enzymatic oxidation of the heme by hydrogen 
peroxide. Surprisingly, the Soret peak of the protein, as well as the bands at 530 and 560 nm 
decreased over time as the protein solution was incubated at room temperature. This observation 
suggested enzymatic heme degradation (fig. 17A). The decrease of the Soret peak and of the 
band at 560 nm isosbestically generated growing bands at 360 and 630 nm respectively, showing 
the formation and accumulation of an intermediate with maximum absorbance at the 
corresponding wavelengths (fig. 17A and inset). As a control, a similar experiment was 
conducted using holoShp, another characterized heme-binding protein in GAS. Interestingly, the 
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Soret peak as well as the β- and α-bands of holoShp did not decrease over time, indicating that 
heme degradation was not taking place (fig. 17B).   
We hypothesized that the observed heme degradation by HupZ in presence of catalase 
was supported by electrons from a reduced cofactor that might have copurified with the protein. 
To test this hypothesis, 2 ml of 20 µM holoHupZ was incubated overnight at 4 °C, with 1 mM of 
potassium ferricyanide. Following gel filtration to remove the ferricyanide, the protein was 
diluted to 10 µM and catalase was added to it to a final concentration of 2 µM. The UV-visible 
absorbance spectrum of the protein solution was subsequently monitored for heme degradation. 
Unlike the untreated protein, the Soret peak of the ferricyanide treated holoHupZ did not 
significantly decrease, indicating that heme degradation was inhibited by the oxidizing agent 
(fig. 17C). 
 
CPR-NADPH as a source of electrons for heme degradation by HupZ  
Heme degradation by HupZ was further assessed in a reaction containing 20 µM of the 
holoprotein, 2 µM of catalase, 25 µg of CPR and 1 mM of NADPH. The spectral changes of the 
reaction were recorded between 350 and 700 nm at room temperature for 1 hour. The peak at 414 
nm and the bands at 530 and 560 nm characterizing heme bound to HupZ decreased significantly 
in the first 30 min then became stagnant.  These variations in the spectral features substantiated 
that the bound heme was degraded over time and that the reaction reached it rate-limiting step or 
was completed within 30 min. Heme degradation in this reaction was accompanied by a slow 
shift of the Soret peak toward 420 nm and generated a growing peak at 670 nm (fig. 18A and 
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inset). In addition, the color of the reaction turned from red to green, suggesting biliverdin 
production (fig. S20). When the reaction was carried out in the absence of CPR or NADPH, the 
spectral changes were similar to that of the holoprotein alone described in fig. 17A (fig. 18B and 
18C). An additional control reaction was carried out using a solution containing 20 µM of heme-
bound NEAT2 (a characterized heme-binding protein in GAS), 2 µM catalase, 25 µg of CPR and 
1 mM of NADPH. No changes in the spectral features of the holoprotein were observed after 1 
hour (fig. 18D). This clearly, showed that NEAT2 does not degrade heme even in the presence of 
the CPR-NADPH system, and that the heme degradation observed in the reaction containing 
holoHupZ was imputable to the enzymatic activity of the latter.    
 
Ascorbic acid as reducing partner for HupZ-catalyzed heme degradation    
The ability of HupZ to degrade heme using ascorbic acid as an electron donor was tested. 
For that, 20 mM of ascorbic acid and 2 µM of catalase were added to 20 µM of holoHupZ and 
the absorbance spectra of the reaction were recorded between 350 and 700 nm for one hour. The 
spectral variations observed for this reaction did not differ significantly from that of the 
holoprotein without addition of a reducing agent (fig. 19A), suggesting that ascorbic acid does 
not significantly contribute to HupZ heme oxygenase activity. The addition of ascorbic acid to 
holoShp did not change the spectral features of the holoprotein over time (fig. 19B). Here again 
the data indicate that the decrease in the characteristic peaks of heme-bound HupZ was catalyzed 
by the protein. Unlike with ascorbic acid, an observable reduction of the bound heme iron 
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precedes an important decrease of the Soret in presence of CPR-NADPH as a source of 
electrons. 
  
Sequence comparison of HupZ and other bacterial heme degrading enzymes 
Bacterial HOs are classified in four major groups based on their structural similarities. 
Representatives of these different groups include, HmuO from C. diphteriae, IsdG from S. 
aureus, ChuS from E. coli and HugZ from H. pylori. To determine whether HupZ belongs to one 
of the characterized HOs families, a multiple sequence alignment was conducted using the web-
based tool, ClustalW2 (EMBL-EBI). The amino acids sequence of HupZ was aligned against the 
sequences of three representatives of each of the four bacterial HOs families. The proteins 
members of each family grouped into a single or two linked clades showing their phylogenetic 
relatedness as expected (fig. 20). Interestingly, HupZ defines a monophyletic group by itself, 
suggesting that it is the prototype of a new family of bacterial HOs (fig. 20). In spite of being 
members of different monophyletic groups, HupZ, MhuD and PigA are at similar evolutionary 
distance from the root with estimated 43%, 42% and 44% evolution respectively. On the other 
hand, the evolutionary distances of the human HO-1 (36%), HmuO (34%) and HugZ (35%) from 
the common ancestor are also very similar. HutZ, HmuZ and PhuS evolved between 26 and 30 % 
from the common ancestor, whereas IsdG, IsdI, HemS and ChuS were the least evolved with 
evolutionary distances between 16 and 18%.   
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Discussion 3 
During infection, GAS obtain and utilize iron from the mammalian host hemoproteins 
[44]. Heme is scavenged from host heme containing proteins by Shr, which subsequently 
transfers its heme to Shp. The latter then conveys heme to a dedicated transporter (SiaABC) for 
its transportation through the thick peptidoglycan layers to the cytoplasm 
[45,53,54,148,152,167]. In the cytoplasm, the imported heme must be degraded through an 
enzymatic process to release iron from the porphyrin center [57]. In most bacteria, HOs carry out 
this function by catalyzing the oxidative cleavage of the meso carbon bridges of the porphyrin at 
the positions α, β, γ or δ [57,59]. In GAS however, the process of heme degradation has not been 
reported since homologues of HOs were not found in the genome of these bacteria.  
In this study we characterized the protein encoded by hupZ, a gene from GAS that is up-
regulated in low iron conditions. The protein lacks a secretion signal, indicating its localization 
in the cytoplasmic compartment. The recombinant HupZ expressed and purified from E. coli 
bound heme to saturation at 1:1 ratio (fig. 16). Thus, it is a novel heme binding protein in GAS 
with potentially an intracellular function. We hypothesized that HupZ is involved in heme 
metabolism and therefore tested its ability to degrade heme. In vitro heme degradation 
experiments require the presence of a suitable reducing equivalent and are typically carried out 
with CPR-NADPH or ascorbic acid as electron donors.  
Heme bound-HupZ, incubated without the addition of an external reducing partner, 
surprisingly degraded heme even in the presence of catalase to prevent non enzymatic oxidation 
of heme by hydrogen peroxide (fig. 17). The inherent heme degradation activity of HupZ was 
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inhibited when the protein was incubated with the oxidizing agent, potassium ferricyanide. These 
results suggested that HupZ was purified with a reduced cofactor serving as a source of electrons 
for heme degradation by the protein. Sequence analysis of HupZ showed that the protein harbors 
a PNPOx-like module which is found in FMN-binding proteins. In addition, the cell lysate of E. 
coli overexpressing HupZ contained a substantial amount of oxidized FMN that was separated 
from the protein during purification (Fig. S18B). Together these observations indicate that the 
reduced cofactor that might have purified with HupZ is FMN hydroquinone (FMNH2). The E 
coli chorismate synthase, is another example of protein which does not bind oxidized FMN when 
purified aerobically but stably binds FMNH2 with high affinity [171,172].    
Furthermore, when ascorbic acid was used as an electron source for heme degradation by 
HupZ, no difference was observed compared to the activity of the protein by itself. This clearly 
indicates that ascorbic acid is not an efficient reducing partner for HupZ function. On the other 
hand, heme degradation by HupZ was considerably enhanced when CPR-NADPH was used as 
reducing equivalent. The first step of the catalytic mechanism of heme oxygenases is the 
reduction of ferric heme to ferrous heme [66]. The spectral shift (from 414 nm to 420 nm) 
observed shortly after NADPH addition indicates the formation of ferrous heme, possibly 
followed by O2 binding. The reaction produced a green color indicative of biliverdin production, 
which was confirmed by the spectral features of the product. In fact, the characteristic peaks of 
bound heme progressively decreased while generating isosbestically new peaks that are 
consistent with biliverdin absorbance spectrum. Heme degradation by HupZ using its reduced 
cofactor or ascorbic acid produced a growing peak at 630 nm while the reaction with CPR-
NADPH generated a growing peak at 670 nm. This suggests that the products generated by these 
79 
 
 
 
reactions may be different biliverdin isomers, or a mixture of isomers in one case or the other, as 
seen with PigA and HugZ [77,92]. Though, further biochemical and chemical analyses are 
necessary to unequivocally characterize all the products generated by HupZ catalyzed heme 
degradation, as well as its regiospecificity.  
Sequence comparison between HupZ and several HOs from different structural families 
showed that this enzyme is not related to any previously characterized HO, although it is at 
similar evolutionary distance as PigA and HmuD from P. aeruginosa and M. tuberculosis 
respectively (fig. 20).  A more conclusive structural comparison of HupZ with other HOs will be 
carried out in the near future, as the resolution of the protein’s structure by crystallography is 
underway. 
In conclusion, we identified and characterized for the first time, a heme oxygenase in the 
Streptococcus genus which was named HupZ. Orthologs of the protein are found in other 
important pathogens such as Streptococcus agalactiae and Streptococcus dysgalactiae. It is the 
representative of a new family of flavoenzymes capable of catalyzing heme degradation using 
electrons from their reduced flavin cofactor. 
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Materials and methods 3 
The bacterial strains, media and antibiotics 
Escherichia coli (E. coli) cells were grown aerobically in Luria–Bertani (LB) medium at 37 °C 
supplemented with 100 µg/ml of ampicillin. The E. coli strains used in this study are listed in 
Table 5. 
 
Recombinant HupZ, NEAT2 and Shp proteins 
The plasmids and primers used in this study are listed in Tables 5 and 6. The cloning of the 
recombinant Shp expressed as a C-terminus fusion to the His-tag was previously described 
(Chapter 2). The construction of HupZ-His and NEAT2-His expression vectors was 
accomplished by TOPO® directional cloning according to the manufacturer instruction 
(Invitrogen, K101-01). The hupZ and shr NEAT2 ORFs were amplified from NZ131 
chromosome using the ZE437/ZE438 and ZE427/ZE428 primer sets respectively and introduced 
into the pET101/D-TOPO vector. The resulting plasmids, pZZ2 and pOM102, code for a HupZ-
His tag and NEAT2-His tag fusion proteins respectively, expressed from the T7 RNA 
polymerase promoter.  
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Proteins expression and purification 
Expression of the recombinant His-tagged proteins was induced overnight at 27 °C with 1mM 
isopropyl β-D-1-thiogalactopyranoside. Cells were harvested and re-suspended in an extraction 
buffer (20 mM Tris pH 8, 100 mM NaCl, 0.1% Triton X-100) with the addition of 0.5 mg/ml and 
Complete, mini-EDTA-free protease inhibitor cocktail tablets (Roche), then lysed by sonication. 
The cells’ pellet was centrifuged and the cleared lysate was then applied to a 5 ml HisTrap HP 
affinity column (nickel column) and purified using a FPLC. Purified proteins were dialyzed in 
sodium phosphate buffer (20 mM sodium phosphate, 500 mM NaCl, pH 7.4) prior to their use 
for experiments. Western blot analysis of the recombinant His-tagged proteins was carried out 
using anti-His antibodies from mouse (Sigma). 
 
Heme reconstitution 
The heme reconstitution experiments were conducted as described in [148]. All the spectra were 
normalized by sustracting the absorbance at 700 nm. 
 
Heme degradation assays 
Heme-HupZ complex was prepared at a hemin:protein ratio of 1.5:1 and excess heme was 
removed by filtration through a PD-10 column (GE Healthcare). Degradation of bound heme by 
HupZ was carried out without electron donor and with two electron donor systems (ascorbic acid 
and NADPH-CPR). Ascorbic acid was added to a final concentration of 20 mM. In the NADPH-
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CPR system, heme-HupZ protein (20 µM) was added to 25 μg of recombinant human NADPH-
cytochrome P450 reductase (CPR). The reaction was initiated by adding NADPH to 1 mM and 
spectra were recorded from 350 nm to 700 nm every 10 min for 1 h. Catalase (bovine liver, 
Sigma-Aldrich) was added to the reaction systems at a final concentration of 2 μM. All reaction 
systems were in 1 ml total volume. 
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Table 5: Strains and Plasmids used in this study 
Name Description Source/Reference 
Strains 
     E.coli  Top10 
    E.coli  BL21 Star 
    
 
  
Host for pOM101 and pZZ2 propagation 
Host for pOM101 and pZZ2 expression  
 
 
Invitrogen 
Invitrogen 
 
Plasmids 
           pOM102 
           pET101/D-TOPO  
           pOM101 
           pZZ2 
 
Expresses NEAT2-His tag from PT7 
Directional TOPO® TA cloning vector  
Expresses Shp-His tag from PT7 
Expresses HupZ-His tag from PT7 
 
This study 
Invitrogen 
Chapter 2 
This study 
 
 
Table 6: Primers used in this study 
 
Name Sequence Description 
ZE427 
 
ATGAATCAAAAACAATTGCGTG 
 
Sense primer for Shr NEAT2 domain 
 
ZE428 
 
AACCTTTGCCTTCTCTGTTGTAAGG 
 
Anti-sense primer for Shr NEAT2 domain 
 
ZE437 ATGATAACACAAGAAATGAAA Sense primer for hupZ  
 
ZE438 GTTACTTTCACTGTTTATTTCTT Anti-sense primer for hupZ 
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GENERAL DISCUSSION 
 
The novel Hb binding motif in Shr NTD   
Hb binding is the first and probably the most important step in the process of heme 
uptake. It is mediated in the vast majority of Gram-negative bacteria by a consensus protein 
motif FRAP/NPNL [1] and by a NEAT domain in most Gram-positive hemoproteins receptors 
[2-6]. Interestingly, the two NEAT domains of Shr do not participate in Hb binding by the 
protein; rather, this function is carried out by an uncharacterized region of Shr NTD. The Hb 
binding NEAT domains of Staphylococcus aureus IsdH and IsdB contain an aromatic motif 
consisting of YYHY or YYHFF [2]. These aromatic motifs as well as the consensus motif found 
in Gram-negatives are absent from Shr NTD, suggesting that the latter contains a novel 
alternative Hb binding motif, which is yet to be identified and characterized [7]. On the other 
hand, NTD contains two copies of a domain of unknown function (DUF1533) that can be 
legitimately hypothesized as the possible Hb binding domains of Shr.  
One possibility for identifying the precise region and amino acid residues required for Hb 
binding by Shr is to conduct partial deletions in order to determine the minimal NTD sequence 
capable of carrying the function. Subsequently, site directed mutagenesis targeting various 
residues may be employed to identify a critical motif. Alternatively, a DNA library from Shr 
NTD’s sequence may be used to achieve a phage display, which will allow for the selection of 
NTD subdomains that show Hb binding. A successful identification of this novel Hb binding 
motif may also serve as the basis for identifying and studying the function of other bacterial 
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proteins in which it can be found. Moreover, an emerging strategy to counter bacterial adaptation 
to antibiotics is the development of molecules that target the iron metabolism of bacteria. One 
approach is the use of chelators and antagonists to inhibit the binding of iron or iron complexes 
such as Hb to their receptors [8]. The kinetic studies herein, demonstrate that Shr must bind Hb 
to efficiently scavenge heme from it. Therefore, the Hb binding motif in Shr constitutes a good 
target for the development of novel therapeutic molecules against GAS. 
 
Significance of heme reduction by Shr   
Shr is copurified with a mixture of ferric and ferrous heme and has the capacity to acquire 
and reduce ferric heme from solution [7,9]. On the other hand, isolated NEAT2 contains mostly 
ferrous heme whereas NEAT1 domain is purified with ferric heme. The data from the kinetic 
studies of heme transfer show that heme is passed from metHb to both NEAT1 and NEAT2 
domains in a direct process, but only NEAT1 efficiently transfers its heme to Shp. This observed 
functional difference may relate to the oxidation status of the heme iron. Examples that support 
this hypothesis and where the redox state of the iron in bound heme affects the properties of the 
hemprotein were reported. In IsdC NEAT domain, the reduction of ferric heme causes heme loss 
by the protein [10].  In addition, the iron axial ligand of IsdA switches from tyrosine to histidine 
when the ferric heme is reduced. A mechanism of closing/opening of the heme binding pocket, 
depending on the oxidative state of the heme iron, was therefore suggested for IsdA [10,11]. 
Moreover, porphyrin with a ferric center binds with higher affinity and stability to IsdH NEAT3 
than porphyrin a ferrous center [12].  
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In the Shr heme reconstitution assay, ferric heme reduction by the protein was more 
pronounced with increasing amounts of bound heme, suggesting that excess of heme may favor 
the process. It is therefore plausible to hypothesize that in high heme conditions, NEAT2 binds 
and reduces ferric heme for storage in the ferrous form, and in low heme situations ferric heme is 
regenerated then passed to NEAT1 for export to Shp. The storage of ferrous heme which is 
supposedly less stable and weakly bound is probably rendered possible by the association of 
ferrous heme with gaseous ligands such as O2, CO or NO in the context of the host environment 
[13,14]. This hypothesis can be tested by conducting comparative kinetic studies of heme 
transfer using stopped-flow spectrophotometer in both aerobic and anaerobic conditions. Rates 
comparisons between reactions using fully reduced and fully oxidized proteins, as well as 
between aerobic and anaerobic transfer reactions, will provide direct evidence of the importance 
for maintaining a certain redox status to achieve an efficient heme transfer. 
 
Basis for the heme degradation by HupZ alone 
We identified for the first streptococcal HO (HupZ), which does not relate in sequence 
and in mechanism to any previously studied HO. HoloHupZ is capable of degrading its bound 
heme without externally supplied reducing partner. This inherent HO activity is inhibited when 
the protein is treated with potassium ferricyanide. These observations suggest that HupZ is 
copurified with a reduced cofactor serving as the electrons donor for heme degradation. In silico 
analysis of HupZ, shows that the protein contains a module from the superfamily of the signature 
domain of the pyridoxamine 5'-phosphate oxidase (PNPOx). The latter is a FMN flavoprotein 
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that catalyzes the oxidation of pyridoxamine-5-P (PMP) and pyridoxine-5-P (PNP) to pyridoxal-
5-P (PLP). In addition to the presence of a PNPOx domain in HupZ, cell lysate of E. coli 
overexpressing the protein displays a yellow color that is retained in the affinity column during 
purification. However, the yellow substance is eluted out of the column in a fraction, which is 
protein-free and separate from that of HupZ. UV-visible spectroscopic analysis shows that the 
absorbance spectrum of the yellow fraction is consistent with the absorbance spectrum of FMN.  
A similar situation is seen with E coli chorismate synthase, which does not bind oxidized 
FMN when purified aerobically [15]. Addition of chorismate synthase to oxidized FMN solution 
did not quench the fluorescence of the cofactor and ultracentrifugation recovered almost all of 
the FMN in the filtrate [16]. This underlines the weak binding of oxidized FMN to chorismate 
synthase and is consistent with the fact that the flavin cofactor is entirely loss during purification 
[15,16]. The purified chorismate synthase, whose activity requires the reduced form of the flavin 
cofactor FMNH2, is fully functional in the presence of FMNH2 and dithionite. This suggests that 
in spite of its inability to associate with oxidized FMN, the protein binds FMNH2, the reduced 
form of the flavin cofactor and its binding affinity was determined to be more than ten times 
higher than the estimated affinity for oxidized FMN binding [15,16]. On the other hand, the 
binding affinity of oxidized FMN to chorismate synthase was increased in the presence of the 
substrate and analogs of the substrate [17].  
It seems possible that like chorismate synthase, HupZ is an FMN binding protein with 
high affinity to the reduced form of the cofactor. Isolation with some reduced FMN may also 
explain the heme degradation in the absence of external reducing agent. This hypothesis can be 
tested by several means. First, as done by Macheroux et al [16], the reduction of FMN and the 
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binding of the reduced cofactor by HupZ can be simultaneously followed in anaerobiosis, by 
monitoring the UV-visible spectrum of FMN in presence of HupZ and the xanthine/xanthine-
oxidase couple as a reducing partner.  Second, the kinetics of inherent heme degradation by 
HupZ alone, and by HupZ in the presence of dithionite and FMN can be conducted in a stopped-
flow spectrophotometer to assess whether reduced FMN increases the rate of heme degradation. 
In the same experiments, the formation of the flavin-quinone intermediates characterizing 
passage from one oxidative state to another can be monitored and correlated with heme 
degradation. Finally, resolving the crystal structure of HupZ in the presence and in the absence 
of FMN will reveal the presence or not of the reduced flavin cofactor.  
  
Potential in vivo reducing partners of HupZ 
The catalytic action of HOs requires reducing equivalents that are provided in mammals 
by CPR-NADPH [18,19]. CPR is a flavoprotein that contains one FAD and one FMN prosthetic 
groups. In plants, cyanobacteria and some eubacteria, the redox system composed of NADPH, 
ferredoxin reductase (FNR) and ferredoxin is suggested to be the reducing partner of the HOs 
[20-22]. A recent study showed that pa-HO (PigA), a HO from P. aeruginosa can efficiently 
degrade heme using FNR, a FAD-containing flavoprotein, as a reducing partner without the 
requirement for ferredoxin [23]. Though, additional FNR mediated heme oxygenation has not 
been shown for any other bacterial system and may not represent the general mechanism for 
bacteria.  
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Studies associating flavins with the catalytic mechanisms of HOs are on the rise. Like 
HupZ, several bacterial HOs were recently described as potentially FMN-binding proteins 
[24,25]. FMN-containing heme enzymes such as flavocytochrome b2 have been extensively 
studied and have been shown to oxygenate the heme substrate using electrons from the flavin 
hydroquinone (FMNH2) [26]. This suggests that the reduced cofactor by itself may be sufficient 
to sustain heme degradation by this class of enzymes in vivo. However, because of the lack of 
experimental evidence so far for FMN binding by these HOs, it cannot be ruled out that HupZ 
may rely on an intracellular reducing partner to carry out its catalytic activity. Therefore, several 
approaches can be used to identify possible reducing partners of HupZ. One perspective is to 
conduct genome mining for flavin-dependent oxidases/reductases in GAS and express the 
recombinant proteins for characterization.  Another possibility is to perform a cross-linking in 
GAS cell lysate followed by immunoprecipitation. Alternatively, purified HupZ may be 
incubated with GAS cell lysate to allow for possible complex formation. Subsequent separation 
of the complex from the lysate may allow fishing out and identifying a putative HupZ partner 
protein.   
 
HupZ heme degradation products 
Heme degradation by the conical HO produces CO, α-biliverdin and free iron [27]. 
However, several bacterial HOs that generate unconventional products were reported. For 
example, along with CO and free iron, IsdG catalyzes heme degradation to produce an oxo-
bilirubin (staphylobilin), whereas PigA and HugZ generate β- and δ-biliverdins [28-30]. On the 
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other hand, the products of heme degradation by HupZ are yet to be characterized. The 
spectroscopic analysis of the heme catabolism reactions showed that the decrease of the Soret 
peak and of the α- and β-bands is accompanied by a concomitant increase around 360 nm and 
630 nm respectively. These spectral features are different from those of all the HOs mentioned 
above and suggest that the product generated may be an unprecedented isomer of biliverdin 
(such as γ-biliverdin) or a mixture of isomers. Furthermore, the reaction of heme degradation by 
HupZ using CPR-NADPH as electrons donor turns from red to green after one hour of 
incubation, consistent with the production of biliverdin.  
Further studies to characterize and unequivocally identify the products generated by 
HupZ-catalyzed heme degradation are underway. For that, the final product will be extracted 
with organic solvents then lyophilized in order to concentrate the products in a minimal volume. 
Additional purification steps will be applied as needed prior to separation of the products by 
HPLC. UV-visible spectroscopy and mass spectrometry will be conducted on the samples 
collected from the HPLC separation. More analyses such as NMR or ENDOR (Electron-Nuclear 
Double Resonance) spectroscopy may be necessary to determine the chemical structures of the 
products. 
In mammals, biliverdin produced by HO-catalyzed heme degradation is reduced into 
bilirubin by a biliverdin-reductase (BVR) [31]. The fate of the biliverdin in bacteria is unknown 
in most cases. A homologue of mammalian biliverdin reductase has been identified only in 
cyanobacteria [32,33]. In Pseudomonas aeruginosa, a bacterial phytochrome BphP, removes 
biliverdin from the catalytic site of PigA and BphO. However, a subsequent transformation of 
the removed biliverdin by BphP was not shown and its physiological relevance is still unclear 
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[22]. Therefore, the fate of biliverdin in non-photosynthetic bacteria remains an intriguing 
question which constitutes the focus of several ongoing investigations.  
It is conceivable that, like in Pseudomonas aeruginosa, a dedicated protein in GAS 
removes the bound biliverdin from HupZ active site and eventually delivers it to a putative 
enzyme for further conversion. Alternatively, a single protein may carry out the dual function of 
biliverdin removal and transformation, in which case it would mechanistically resemble the 
mammalian BVR. Strategies like those suggested in the section above may be adopted to look 
for proteins involved in biliverdin conversion or excretion from the cell. 
 
In summary, this study explored the role of Shr in heme acquisition by GAS and 
established the protein as a new type of composite NEAT-containing receptor. It also deciphered 
the molecular mechanism of heme scavenging and transfer by Shr from metHb, providing the 
first example of intra-molecular heme exchange between NEAT domains. In addition, this work 
solved a long-standing enigma by identifying and characterizing for the first time a heme 
oxygenase in the Streptococcus genus (HupZ). Importantly, this study provided new direct 
evidence that associates flavins with heme metabolism in bacteria, thus setting a new direction in 
the field of heme acquisition and utilization by pathogens.     
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Figure 1: (A) Schematic representation of the sia operon and the Shr protein. (B) Heme 
relay in Group A Streptococcus. 
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Figure 2: Catalytic mechanism of heme oxygenases [1]. 
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Figure 4: Hemin binding and reduction by rShr. (A) SDS-PAGE showing purified rShr. (B) 9 
μM Shr (blue line) was treated with 10 mM of DTT (red line) or 30 μM ferricyanide (FCN) 
(green line). Histag elution buffer containing 10 mM DTT was used as a blank for DTT-treated 
Shr spectrum and excess ferricyanide was removed from the protein sample by dialysis in 
phosphate buffer. (C) An increase of heme bound to Shr (3 μM) as increasing concentrations (1 
μM, red; 3 μM, green; 5 μM, purple; 10 μM, blue; or 20 μM, orange) of hemin were added to 
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the protein is shown by the sharp peak at 414 nm. Hemin reduction is indicated by the growing 
absorbance at 427 nm and at ~540 and ~564 nm. The corresponding hemin chloride 
concentrations in Histag elution buffer served as blanks for the UV-visible scans (see figure S2). 
The insert magnifies the 500 nm – 700 nm region. (D) UV-visible spectra of rShr following the 
addition of 20 μM hemin (red line) and treatment with ferricyanide (blue line). Hemin reduction 
shown by the presence of a Soret peak at 427 nm and by the peaks at ~540 and ~564 nm (red 
spectrum) is reversed by the addition of ferricyanide (blue spectrum). 
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Figure 5: Heme binding by Shr fragments. (A) Schematic representation of NTD, NTD-N1 
and NEAT2. LP: Leader Peptide; ST: Strep-Tag; DUF: Domain of Unknown Function 1533; 
NEAT: NEAr Transporter domain; (B) SDS-PAGE showing purified recombinant Shr fragments 
(1) Molecular weight marker, (2) NEAT2, (3) NTD, (4) NTD-N1. The UV-visible spectra of 
NEAT1 (C), NTD (D), NTD with additions of hemin chloride (1 μM, red; 5 μM, green; or 10 
μM, purple) (E) and NEAT2 (F). (G) UV-visible spectra of NEAT2 following titration with 20 
μM hemin (blue). The red and green lines, respectively, represent the spectrum 5 min and 24 h, 
after addition of 6 μM ferricyanide. The insert magnifies the 400 nm – 460 nm region, showing 
the shifts in the Soret peaks. The Strep-tag wash buffer alone was treated exactly the same way 
as the protein solution, and used as blank for UV-visible scan. 
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Figure 6: (A) Methemoglobin binding by Shr fragments. ELISA showed methemoglobin 
binding by rShr (crosses), NTD (black squares), and NTD-N1 (triangles). In contrast, NEAT2 
(dots) or BSA (diamonds) did not bind methemoglobin. ELISA testing apohemoglobin binding 
by NTD (Red squares) showed no binding. The plates were coated with rShr or the Shr 
fragments and subsequently reacted with increasing concentrations of methemoglobin or 
apohemoglobin. Protein binding was detected with anti-hemoglobin antibodies as described in 
Materials and Methods. (B) Direct detection of immobilized holohemoglobin (triangles) and 
apohemoglobin (squares) with anti-hemoglobin antibodies. Uncoated wells (diamonds) were 
used as a negative control. Each datum point in sections A and B represents the mean ± SD 
(represented by the error bars) from data from at least two independent experiments done in 
triplicates. 
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Figure 7: Binding of extracellular matrix proteins by Shr. Elisa assay showing fibronectin 
(A) and laminin (B) binding by rShr (crosses) and NEAT2 (dots). NTD-N1 (triangles) slightly 
bound fibronectin but did not bind laminin. In contrast, NTD (squares) or BSA (diamonds) did 
not bind fibronectin or laminin. The plates were coated with rShr or Shr fragments and 
subsequently reacted with increasing concentrations of fibronectin or laminin as described in 
Materials and Methods. Each datum point in panels A and B stands for the mean ± SD (shown 
by the error bars) of three independent experiments done in triplicates.  
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Figure 8: Heme transfer from methemoglobin to apoNTD-N1. (A) UV-visible spectra of 10 
μM apoNTD-N1 after contact with methemoglobin (red) or hemin chloride (blue) and 10 μM 
apoNTD-N1 (green). (B) Western blot analysis of the fraction containing the Hb washes and 
NTD-N1 elution. Proteins (50 ng/well) were detected with anti-Hb (upper panel) or anti-Shr 
(lower panel) antibodies. (1) MW Marker; (2) purified apoNTD-N1; (3) Hb fraction; (4) NTD-
N1 after Hb flow; (5) Empty lane; (6) Hb 50 ng ; (7) Hb 100 ng.  
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Figure 9: Growth analysis of shr deletion mutants. (A) Schematic representation of the in 
frame deletions created in Shr. WT: wild type; ΔNEAT1:  a deletion of the NEAT1 domain; 
ΔNEAT2:  a deletion of the NEAT2 domain; ΔNEAT1-2:  a deletion of both NEAT1 and 
NEAT2 domains. Panels B-E describe the characterization of the constructed GAS mutants (B) 
The first panel shows PCR analysis of the chromosomal shr gene. Total RNA from each strain is 
shown in the second panel. The third and fourth panels respectively show RT-PCR analysis of 
the expression of shr (ZE106/126 primers) and siaA (204A-Fwd/Rev primers) genes. (C) 
Western blot showing the expression of the corresponding Shr protein variants. WT: wild type 
GAS (strain NZ131); ΔN1: NEAT1 mutant (strain ZE4925); ΔN2: NEAT2 mutant (strain 
ZE4926); ΔN1N2: NEAT1-2 mutant (strain ZE4929); Shr::spec: non polar null shr mutant 
(strain ZE4912); ΔN1N2/pXL14: NEAT1-2 mutant complemented with shr (strain ZE4924). A 1 
ml volume of each culture at OD600 = 1 was processed and 20 μl of the prepared samples were 
loaded per well. (D) Growth in CDM in the presence of 20 μM of iron. (E) Growth in CDM with 
2 mM dipyridyl and no additional source of iron.  (F) Growth in CDM with 2 mM dipyridyl and 
20 μM of methemoglobin, as the sole source of iron. Diamonds: wild type GAS (strain NZ131); 
Squares: ΔNEAT1 mutant (strain ZE4925); Triangles: ΔNEAT2 mutant; Crosses: ΔNEAT1-2 
mutant; Dots: null shr mutant. (G) Growth of wild type and Shr complemented strains in CDM 
with 2 mM dipyridyl and 20 μM of hemoglobin as the sole source of iron. Diamonds: wild type 
GAS; Crosses: ΔNEAT1-2 mutant complemented with shr; Dots: Null shr mutant (shr::aad9) 
complemented with shr (strain ZE4924). Cells were grown in a 96 well microplate at 37 °C for 
24 h and growth was monitored at OD600. Each datum point in all of the panels represents the 
mean of at least two independent experiments performed in triplicates. For clarity purpose the 
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SD (represented by the error bars) is shown only in panel F (in which significant growth 
differences are found between the strains). 
 
 
Figure 10: Heme acquisition from MetHb. (A) UV-visible absorbance spectra of apoNEAT1 
before (dashed line) and after incubation with metHb (smooth line).  The Soret peak at 412 nm 
indicates ferric heme binding by NEAT1. (B) UV-visible absorbance spectra of apoNEAT2 
(dashed line) and apoNEAT2 after incubation with metHb (smooth line).   A major Soret peak at 
426 nm along with peaks at 410 nm, 530 and 560 nm indicate a mixture of bound ferric and 
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ferrous heme. All the absorbance spectra were corrected by subtracting their corresponding 
background absorbance at 700 nm. 
 
Figure 11: Kinetics of heme transfer from metHb to apoNTD-N1. (A) Traces of the 
absorbance at 414 nm of the reaction containing 2.5 μM of apoNTD-N1 and various 
concentrations of metHb recorded as a function of time. Absorbance variations at 414 nm as a 
function of time best fitted a triple exponential at all concentrations of metHb tested (equation 2). 
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 (B) Observed rate constants for the first phase of heme transfer from metHb to apoNTD-N1 
plotted as a function of metHb concentration and fitted using the equation: kobs1 = k1 + k2 * (Keq / 
(Keq + x)) (R2 = 0.99). (C) The observed rate constants for the second (kobs2) and third (kobs3) 
phases as functions of metHb concentration. All concentrations of metHb were based on heme 
bound absorption. 
 
 
Figure 12: Kinetics of heme transfer from metHb to the full-length Shr. (A) Traces of the 
absorbance at 414 nm of the reaction containing 2.5 μM of apoShr and various concentrations of 
metHb recorded as a function of time. Absorbance variations at 414 nm as a function of time best 
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fitted a triple exponential at all concentrations of metHb tested (equation 2).   (B) Observed rate 
constants for the first phase of heme transfer from metHb to apoShr plotted as a function of 
metHb concentration. kobs1 was fitted using the equation: kobs1 = 1+[6.5x / (12 + x)] (R2 = 0.99). 
(C) The observed rate constants for the second (kobs2) phase were fitted using the equations: kobs2 
= 2.3x / (138 + x) (R2 = 0.99).   
 
 
Figure 13: Kinetics of heme transfer from Shr NEAT domains to apoShp. Various 
concentrations of holoNEAT1 or holoNEAT2 were mixed with apoShp (2.5 μM). (A) 
Representative trace of the time course of heme transfer from holoNEAT1 to apoShp. (B) The 
observed rate constants for the fast phase of heme transfer from holoNEAT1 to apoShp plotted 
as a function of [holoNEAT1] was fitted using the equation: y = 2.5x (R2 = 0.99). (C) The 
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observed rate constants for the slow phase of heme transfer from holoNEAT1 to apoShp plotted 
as a function of [holoNEAT1] was fitted using the equation: y = 0.017x. (R2 = 0.89). (D) 
Representative trace of the time course of heme transfer from holoNEAT2 to apoShp. (E) The 
plot of the observed rate constants of the heme transfer from holoNEAT2 to apoShp as a function 
of [holoNEAT2] fitted using the equation: y = 0.01x / (x+25). (R2 = 0.99) 
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Figure 14: Heme transfer from holoNEAT1 to apoNEAT2. (A) UV-visible absorbance 
spectra of apoNEAT2 before (dashed line) and after incubation with holoNEAT1 (smooth line).   
ApoNEAT2 upon incubation with holoNEAT1 showed Soret peaks at 411 and 426 nm as well as 
peaks at 530 and 560 nm, indicating a mixture of bound ferric and ferrous heme. (B) Kinetics of 
heme transfer from holoNEAT1 to apoNEAT2. The observed rate constants plotted as a function 
of [holoNEAT1] increased in [holoNEAT1]-dependent manner and was fitted using the 
equation: y = 0.14x (R2 = 0.94).   
  
                                       
Figure 15: Proposed model of heme acquisition by the S. pyogenes Sia system. Shr binds 
metHb through NTD and forms an intermediate protein complex, which may facilitate direct 
heme transfer from metHb to NEAT1 and NEAT2 and eventually the release of heme from 
metHb in solution. Heme scavenged by NEAT1 is rapidly transferred to Shp for delivery into the 
cell by the SiaABC transporter.  Heme acquired by NEAT2 is stored and transferred back to 
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NEAT1 when needed, possibly when heme availability is limiting. The full and dashed arrows 
indicate the heme flow under low and high heme availability, respectively.   
 
 
 
Figure 16: Heme binding by HupZ. Various concentrations of hemin chloride were added to 
40 µM HupZ in 1 ml of 20 mM sodium phosphate buffer. The corresponding hemin 
concentrations in 1 ml of the buffer without protein were used as blanks (A). The differential 
absorbance at 414 nm plotted as a function of [hemin] shows a binding stoichiometry of 1:1 (B). 
The spectra of free heme in the buffer (C), showing major differences with those of bound heme 
seen in (A). 
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Figure 17: Heme degradation by HupZ without external electron donors. (A) HupZ-
catalyzed heme degradation in absence of exogenous reducing equivalent. The inset magnifies 
the region between 500 and 700 nm showing the decrease of the bands at 530 and 560 nm and 
the concomitant increase of a band at 630 nm. The arrows indicate the direction of the changes. 
(B) The spectral features of heme bound to Shp did not change over time, indicating absence of 
heme degradation.  (C) Inhibition of HupZ catalytic activity by potassium ferricyanide. 
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Figure 18: heme degradation by HupZ using CPR-NADPH as reducing equivalent. (A) 
Heme degradation with CPR-NADPH as source of electrons. The inset magnifies the region 
between 500 and 700 nm showing the decrease of the bands at 530 and 560 nm and the 
concomitant increase of a band at 670 nm. The arrows indicate the direction of the changes. The 
reaction in absence of CPR (B) or NADPH (C) did not enhance heme degradation by HupZ. (D) 
Control reaction carried out with heme bound NEAT2 and the CPR-NADPH system. 
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Figure 19: heme degradation by HupZ with ascorbic acid as a source of electrons. (A) 
Heme degradation by HupZ using ascorbic as a reducing partner. The inset magnifies the region 
between 500 and 700 nm showing the decrease of the bands at 530 and 560 nm and the 
concomitant increase of a band at 630 nm. The arrows indicate the direction of the changes. (B) 
Control reaction carried out with heme bound Shp and ascorbic acid. 
 
 
Figure 20: Phylogenetic tree of bacterial heme oxygenases generated from ClustalW2 
(EMBL-EBI). The number displayed for each HO represents its evolutionary distance from the 
root. 
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Figure S1: NEAT alignment. Sequence alignment of the heme-binding NEAT domains of 
IsdA, IsdH, IsdB, IsdC, and the two NEAT domains of GAS Shr.  Alignment was generated 
using the ClustalW program. Important residues found in the heme-binding pocket are indicated 
by the black frames [2].   The residues corresponding to K75 and S82 of IsdA heme binding 
pocket are conserved in Shr NEAT1 and NEAT2. The conserved iron-coordinating Y166 in Isd, 
however, is absent from Shr NEAT domains and the Isd-conserved Y170 is present in Shr 
NEAT1 only.  The aromatic residues at position 87 and 113 are present in Isd but not in Shr. 
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Figure S2: UV-visible spectra of hemin chloride. Increasing concentrations of hemin chloride 
were added to Histag elution buffer and the spectra were determined as described in Material and 
methods. 
 
 
Figure S3: Heme reconstitution of NEAT2 protein fragment. Increasing concentrations (1 
μM, red; 3 μM, green; 5 μM, purple; 10 μM, light blue and 20 μM, orange) of hemin chloride 
were added to NEAT2 protein in Strep-tag elution buffer. The corresponding hemin chloride 
concentrations were added to Strep-tag elution buffer and used as blanks for the UV-visible 
scans.  
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Figure S4: Binding of rShr to holo and apo hemoglobin. Binding of rShr to microtiter plate 
wells coated with 200 nM Goat IgG (circles), 200 nM apohemoglobin (squares), and 200 nM 
holohemoglobin (triangles). Increasing concentrations of rShr were incubated in wells overnight 
at 4 ºC. Bound protein was detected with polyclonal anti-Shr antibodies and anti-rabbit AP 
conjugated antibodies. The experiments were repeated twice and the values are derived from the 
means of triplicate wells.    
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Figure S5: Heme transfer from methemoglobin to apoNTD-N1. UV-visible spectra of 
apoNTD-N1 (black), apoNTD-N1 after 5 min incubation with methemoglobin (blue) and 
apoNTD-N1 after 75 min incubation with methemoglobin (red). ApoNTD-N1 (100 nmoles in 2 
ml Strep-tag wash buffer) was incubated with methemoglobin (50 nmoles in phosphate buffer 
solution). NTD-N1 was separated from methemoglobin through a Strep-Tactin column following 
an extensive wash with Strep-tag wash buffer. 
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Figure S6: Growth phenotype of wild type GAS and Shr mutants. (A) In presence of 2 mM 
dipyridyl and 5 μM of human hemoglobin as sole source of iron. (B) In presence of 2 mM 
dipyridyl and 10 μM of human hemoglobin as sole source of iron. (C) In presence of 2 mM 
dipyridyl and 60 μM of human hemoglobin as sole source of iron. Cells were grown in a 96 well 
microplate at 37 °C for 24 h and the growth was monitored at OD600.  Diamonds: wild type GAS; 
Crosses: ΔNEAT1-2 mutant (strain ZE4929); Dots: non polar null shr mutant (shr::aad9, strain 
ZE4912). The vertical bars indicate the standard deviation between triplicates of two repeated 
experiments. 
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Figure S13: Spectral differences between metHb and NTD-metHb complex. (A) UV-visible 
spectra of metHb and NTD-metHb, MBP-metHb mixtures. (B) UV-visible spectrum of 4.5 μM  
NTD. 
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Figure S18: characterization of the purified recombinant HupZ. SDS-PAGE of HupZ 
elution fractions shows single bands consistent with the expected size of the protein (A). UV-
visible absorbance spectra of the yellow eluate showing the characteristic features of oxidized 
FMN (B) and of HupZ as purified (C). The insets show an enlarged scale of the 300-700 nm and 
300-600 nm regions, respectively.   
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Figure S19: UV-visible absorbance spectra of heme bound HupZ and of the heme-pyridine 
adduct. 
 
 
Figure S20: Characteristic color of HupZ-CPR-NADPH heme degradation reaction. The 
starting color (A) and the ending color (B) of the reaction showing the change from red to green. 
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Scheme 1: proposed kinetic model of heme transfer from metHb to apoNTD-N1  
 
 
 
Scheme 2: proposed kinetic model of heme transfer from metHb to apoShr 
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Scheme 3: First and second phases of heme transfer from holoNEAT1 to apoShp 
HoloNEAT1* and apoNEAT1* represent alternative species of holoNEAT1 and apoNEAT1, 
respectively. 
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